1. 106568849 一种沙格列汀中有关物质的检测方法
CN
19.04.2017
G01N 30/02 Loading...
G01N 30/02
Loading...
201510653584.7
深圳翰宇药业股份有限公司
陈泽汉
G01N 30/02
Loading...
本发明公开了一种沙格列汀中有关物质的检测方法，该方法采用反相高效液相色谱法，选用十八烷基硅烷键合硅胶色谱柱，以高氯酸钠溶液-甲醇-乙腈为流动相进行梯度洗脱，流速为0.4-1.0mL/min，柱温20-40℃，样品的检测波长为210-220nm。
2. 104496952 一种达格列净的合成方法
CN
19.04.2017
C07D 309/10 Loading...
C07D 309/10
Loading...
102014000712567
深圳翰宇药业股份有限公司
陈新亮
C07D 309/10
Loading...
本发明涉及一种达格列净的合成方法，采用卤代苯衍生物和2,3,4,6,‑四乙酰氧基‑α‑D‑吡喃葡萄糖溴化物为原料，省去了原方法中的还原反应和乙酰基化反应，缩短了反应工艺步骤，提高了总收率。将苯锂试剂制备成反应较温和的铜锂试剂或格氏试剂中间体，减少了副产物的产生，反应温度控制在‑10℃以下即可。
3. 106560177 一种曲格列汀药物组合物及其制备方法
CN
12.04.2017
A61K 9/44 Loading...
A61K 9/44
Loading...
102015000642462
深圳翰宇药业股份有限公司
戴荣欢
A61K 9/44
Loading...
本发明提供一种曲格列汀骨架控释片，其包括骨架片芯和控释包衣膜，其中骨架片芯由药物层和推动层构成，控释包衣膜由半透膜高分子材料和致孔剂构成，并且药物层一侧具有释药小孔。相应地，本发明还提供制备本发明的曲格列汀骨架控释片的方法，包括(1)将药物层和推动层各组分分别过筛、混合均匀；(2)将药物层和推动层压制成双层骨架缓释片芯；(3)用含有半透膜高分子材料和致孔剂的包衣液进行包衣；(4)在包衣片的药物层一侧打释药小孔。
4. 106551927 包含维格列汀和盐酸二甲双胍的药物组合物及其制备方法
CN
05.04.2017
A61K 31/40 Loading...
A61K 31/40
Loading...
201510639366.8
深圳翰宇药业股份有限公司
颜携国
A61K 31/40
Loading...
本发明属于药物合成技术领域，公开了一种包含维格列汀和盐酸二甲双胍的药物组合物及其制备方法。在本发明中，选用一定的辅料并且将其调配在特定用量范围内，先对盐酸二甲双胍进行单独制粒，然后再将制备的盐酸二甲双胍颗粒与维格列汀和药学上可接受的辅料进行混合制粒，从而有效改善了片剂制备过程中的稳健性和可控性，重现性好，生产出稳健、可控、重现性好的片剂，适合工业化生产。
5. 106551914 一种达方吡啶缓释片及其制备方法
CN
05.04.2017
A61K 9/22 Loading...
A61K 9/22
Loading...
201510633489.0
深圳翰宇药业股份有限公司
刘慧
A61K 9/22
Loading...
本发明属于药物制剂学领域，具体涉及一种达方吡啶缓释片及其制备方法。本发明所述达方吡啶缓释片包括含达方吡啶的片芯，所述含达方吡啶的片芯由达方吡啶、缓释材料、粘合剂、填充剂、助流剂、润滑剂组成。本发明所述达方吡啶缓释片处方简单，含量均匀度-远低于限度要求，释放度批间差异小，重现性好，适宜工业化生产。本发明所述达方吡啶缓释片的制备方法操作简单，含有达方吡啶的粘合剂与缓释材料、填充剂混合均匀湿法制粒能够减少达方吡啶粉末对操作人员的刺激，提高劳动保护，同时降低生产成本。
6. 106554405 一种多肽及其用途、制备方法
CN
05.04.2017
C07K 14/575 Loading...
C07K 14/575
Loading...
201510641027.3
深圳翰宇药业股份有限公司
朱日成
C07K 14/575
Loading...
本发明涉及多肽合成领域，特别涉及一种多肽及其用途、制备方法。该多肽具有(Ⅰ)、(Ⅱ)、(Ⅲ)所示的氨基酸序列中任意一个：(Ⅰ)、普兰林肽的第1位、第9位、第20位、第30位、第34位和/或第36位的氨基酸被修饰的氨基酸序列；(Ⅱ)、具有如(Ⅰ)所示的氨基酸序列经取代、缺失或添加一个或几个氨基酸获得的氨基酸序列；(Ⅲ)、与(Ⅰ)或(Ⅱ)具有至少70％同源性的序列。本发明普兰林肽衍生物具有延长的药代动力学性质及较优的药效学性质。因此，本发明胰岛淀粉样多肽衍生物无须与现有的醋酸普兰林肽一样频繁地注射。本发明方法新颖、合成条件温和、工艺简单且工艺稳定。
7. 106556651 检测丙氨酸、赖氨酸、谷氨酸和/或酪氨酸的方法
CN
05.04.2017
G01N 30/02 Loading...
G01N 30/02
Loading...
201510640989.7
深圳翰宇药业股份有限公司
喻禹铭
G01N 30/02
Loading...
本发明涉及药物分析技术领域，尤其涉及检测丙氨酸、赖氨酸、谷氨酸和/或酪氨酸的方法。本发明提供的方法采用LC/MS对待测品进行检测，通过外标法定量，能够具有良好的准确性和灵敏性，并能适用于醋酸格拉替雷的质量检测。实验表明，本发明提供的方法能够准确对丙氨酸、赖氨酸、谷氨酸和/或酪氨酸进行准确的定量，加标回收率为98.1％～101.7％；重复性良好，连续进样5针RSD皆小于2％；并且，最低检测限不足1.1μg/mL，灵敏度良好。
8. 106554406 一种乌拉立肽的合成方法
CN
05.04.2017
C07K 14/58 Loading...
C07K 14/58
Loading...
201510641888.1
深圳翰宇药业股份有限公司
戴政清
C07K 14/58
Loading...
本发明涉及医药技术领域，公开了一种乌拉立肽的合成方法。本发明所述合成方法将保护的Tyr与离子液体载体在偶联体系的作用下偶联；然后按照乌拉立肽的肽序固相合成剩余保护氨基酸，获得乌拉立肽线性肽离子液体肽载体，然后裂解获得线性肽粗品；线性肽粗品氧化获得形成二硫键的乌拉立肽粗品；乌拉立肽粗品纯化获得精肽。本发明以室温离子液体载体替代了传统固相合成中的树脂载体以及氧化环节中的有机溶剂和水的液相氧化介质，使得固相合成的乌拉立肽线性肽粗肽纯度得到显著提高，同时氧化反应时间可大幅减少，操作方便，避免有机废液的产生。
9. 106554391 一种海洋生物肽Xen2174的合成方法
CN
05.04.2017
C07K 7/08 Loading...
C07K 7/08
Loading...
201510626591.8
深圳翰宇药业股份有限公司
陈学明
C07K 7/08
Loading...
本发明涉及一种Xen2174肽的合成方法，先固相合成线性肽，然后定向形成两对二硫键，即通过固相氧化形成第一对二硫键(即4-13二硫键)，通过液相辣根过氧化物酶氧化形成第二对二硫键(即5-10二硫键)，粗肽经纯化得到Xen2174精肽。该方法具有操作简单、工艺简化、合成条件温和、环境友好、经济效益高、可规模化生产等优点。
10. 106551915 肠溶组合物及其制备方法
CN
05.04.2017
A61K 9/32 Loading...
A61K 9/32
Loading...
201510641777.0
深圳翰宇药业股份有限公司
郑春莲
A61K 9/32
Loading...
本发明涉及药物技术领域，特别涉及肠溶组合物及其制备方法。本发明的GLP-1类似物肠溶组合物能有效避免了生物酶的破坏，其在肠道中能保持较高生物利用度。本发明的肠溶组合物的释放部位在人体的结肠部位。本发明试验结果表明：采用添加pH值稳定剂来增加GLP-1类似物阻止其降解及下降同时添加一种添加碱性表面活性剂，形成胶束，增加其溶解度，提高溶出度。
11. 106554407 一种乌拉立肽的合成方法
CN
05.04.2017
C07K 14/58 Loading...
C07K 14/58
Loading...
201510644646.8
深圳翰宇药业股份有限公司
戴政清
C07K 14/58
Loading...
本发明涉及医药技术领域，公开了一种乌拉立肽的合成方法。本发明所述合成方法将乌拉立肽线性肽粗肽或精肽加入到熔点在20℃以下的离子液体中，在碱性环境下氧化0.5-3h，获得形成二硫键的乌拉立肽粗品。本发明以室温离子液体替代了传统氧化环节中的有机溶剂和水的液相氧化介质，使得固相合成的乌拉立肽粗肽纯度以及精肽总收率得到显著提高，同时氧化反应时间可大幅减少，操作方便，避免有机废液的产生。
12. 106554296 3H）保护的氨基酸及其制备方法
CN
05.04.2017
C07C 303/22 Loading...
C07C 303/22
Loading...
201510640945.4
深圳翰宇药业股份有限公司
陶志强
C07C 303/22
Loading...
本发明涉及一种氨基酸保护基，具体涉及一种用于制备纯化的具有良好亲水性Fmoc(SO3H)保护氨基酸及其制备方法。其主要结构如化学式II所示，其中，R为丙氨酸(Ala)、缬氨酸(Val)、亮氨酸(Leu)、异亮氨酸(Ile)、脯氨酸(Pro)、苯丙氨酸(Phe)、色氨酸(Trp)、蛋氨酸(Met)、甘氨酸(Gly)、丝氨酸(Ser)、苏氨酸(Thr)、半胱氨酸(Cys)、酪氨酸(Tyr)、天冬酰胺(Asn)谷氨酰胺(Gln)、赖氨酸(Lys)、精氨酸(Arg)、组氨酸(His)、天冬氨酸(Asp)或谷氨酸(Glu)的侧链。
13. 106554301 一种沙格列汀关键中间体的制备方法
CN
05.04.2017
C07D 209/52 Loading...
C07D 209/52
Loading...
201510641004.2
深圳翰宇药业股份有限公司
陶志强
C07D 209/52
Loading...
本发明涉及一种(1S,3S,5S)-3-(氨基羰基)-2-氮杂双环[3.1.0]己烷-2-甲酸叔丁酯的制备方法，其包括以下步骤：1)Boc-L-焦谷氨酸甲酯通过三乙基硼氢化锂还原，再用三氟乙酸酐脱水得到(S)-1-N-叔丁氧羰基-2,3-二氢-2-吡咯甲酸乙酯；2)将(S)-1-N-叔丁氧羰基-2,3-二氢-2-吡咯甲酸乙酯在碱性条件下的水解反应、加DIPEA成盐后得到(S)-1-N-叔丁氧羰基-2,3-二氢-2-吡咯甲酸N,N-二异丙基乙胺盐；3)将步骤2)所得(S)-1-N-叔丁氧羰基-2,3-二氢-2-吡咯甲酸N,N-二异丙基乙胺盐进行酰胺化后得到(S)-1-N-叔丁氧羰基-2,3-二氢-2-吡咯甲酰胺；4)将(S)-1-N-叔丁氧羰基-2,3-二氢-2-吡咯甲酰胺以手性镍催化剂催化环丙化反应得到单一构型的目标产物(1S,3S,5S)-3-(氨基羰基)-2-氮杂双环[3.1.0]己烷-2-甲酸叔丁酯(SM1)。
14. 106556652 富马酸二甲酯原料药的质量检测方法
CN
05.04.2017
G01N 30/02 Loading...
G01N 30/02
Loading...
201510641867.X
深圳翰宇药业股份有限公司
李勇
G01N 30/02
Loading...
本发明涉及分析检测领域，尤其涉及富马酸二甲酯原料药的质量检测方法。本发明提供的方法以HPLC定量检测富马酸二甲酯原料药中有效成分及杂质的方法，该方法准确性高，灵敏度高，重复性好。实验表明，采用本发明提供的方法，连续六针进样，峰面积的RSD值不超过5％，说明重现性较好；对不同物质的加标回收率为89％～98.5％，说明准确度良好；经计算，本发明的方法对富马酸二甲酯原料药中有效成分及杂质的最低检测限皆低于0.01μg/mL，说明本发明提供的方法的灵敏度良好。
15. 106554389 一种爱啡肽的合成方法
CN
05.04.2017
C07K 7/06 Loading...
C07K 7/06
Loading...
201510626534.X
深圳翰宇药业股份有限公司
陈学明
C07K 7/06
Loading...
本发明提供一种液相制备多肽药物爱啡肽的方法。该方法包括：以Fmoc-Pro-OH和H-Cys(Mmt)-NH-Dmcp制备中间体；按照爱啡肽的肽序，在中间体上依次偶联-Trp(Trt)、-Asp(OtBu)、-Gly、-HArg(Pbf)、-Mpa(Mmt)；加入包含脱保护基团试剂的混合溶液反应；加入氧化剂制备爱啡肽。在所述方法中，各偶联步骤反应结束后仅进行洗涤处理，无需分离纯化。该方法合成条件温和、工艺简单且工艺稳定，适合工业化连续生产。
16. 106554306 达方吡啶的制备方法
CN
05.04.2017
C07D 213/73 Loading...
C07D 213/73
Loading...
201510631805.0
深圳翰宇药业股份有限公司
陈学明
C07D 213/73
Loading...
本发明涉及一种达方吡啶的制备方法，包括以下步骤：1)将氨基树脂和异烟酸通过偶联剂制备异烟酸酰胺树脂；2)以裂解液脱除树脂，制备异烟酸酰胺；3)将步骤2)所得异烟酸酰胺通过降解试剂和碱，经霍夫曼降解得到达方吡啶。
17. 104447753 一种西他列汀及其中间体的制备方法
CN
29.03.2017
C07D 487/04 Loading...
C07D 487/04
Loading...
102013000425348
深圳翰宇药业股份有限公司
姚志军
C07D 487/04
Loading...
本发明涉及药物合成领域，特别涉及一种西他列汀及其中间体的制备方法。式III所示化合物的制备方法为在第一有机溶剂存在的条件下，取式I所示化合物和式II所示化合物，在还原剂和有机酸的作用下发生还原胺化反应，得到式III所示化合物；还原剂选自氰基硼氢化钠或三乙酰氧基硼氢化钠。本发明提供的制备方法无需使用贵重金属作为催化剂，降低了成本，简化了合成过程，提高了收率，使西他列汀的化学纯度和光学纯度均得到了提高；其中，R为甲基或氨甲酰基；Ar为苯基、单取代苯基或多取代苯基。
18. 104072605 一种替度鲁肽的制备方法
CN
29.03.2017
C07K 14/605 Loading...
C07K 14/605
Loading...
102013000102450
深圳翰宇药业股份有限公司
宓鹏程
C07K 14/605
Loading...
本发明涉及多肽药物制备方法领域，尤其涉及一种替度鲁肽制备方法。该方法以Asp‑Gly二肽及氨基酸为原料，制备第一多肽片段；合成C端多肽片段‑树脂及中间多肽片段；按照替度鲁泰肽序，在C端多肽片段‑树脂上依次偶联中间多肽片段和第一多肽片段，制得替度鲁肽树脂；取替度鲁肽树脂经裂解、纯化，即得；Asp‑Gly二肽中Gly侧链保护基为Dmb或Hmb；第一多肽片段具有SEQ ID NO：1或SEQ ID NO：2所示氨基酸序列；C端多肽片段具有如SEQ ID NO：3、SEQ ID NO：4或SEQ ID NO：5所示氨基酸序列；中间多肽片段为1～3个。该方法避免了五元环结构的形成，提高纯度。
19. 104045707 一种替度鲁肽的纯化方法
CN
08.02.2017
C07K 14/605 Loading...
C07K 14/605
Loading...
102013000080960
深圳翰宇药业股份有限公司
赵忠卫
C07K 14/605
Loading...
本发明涉及医药工艺领域，公开了一种替度鲁肽的纯化方法。该方法将替度鲁肽粗品用乙腈醋酸混合水溶液溶解，然后加水稀释至乙腈和醋酸的体积百分比之和为10%‑30%，再用RP‑HPLC进行梯度洗脱，分离出纯度在95%以上的替度鲁肽流份备用，分离出纯度在90%‑95%的替度鲁肽流份再次进行洗脱，混合在95%以上的替度鲁肽流份调整乙腈体积百分比低于15%、pH值为6‑7后析晶，离心后所得固体为纯品。本发明用醋酸乙腈混合溶解体系对替度鲁肽粗品前处理，而后以适宜的流动相进行RP‑HPLC梯度洗脱，最后通过盐析和脱盐纯化出品质较高的替度鲁肽纯品，与现有RP‑HPLC纯化方法相比，提高了纯化效率和收率。
20. 104072604 一种替度鲁肽的聚乙二醇偶合物及其固相制备方法
CN
08.02.2017
C07K 14/605 Loading...
C07K 14/605
Loading...
102013000102207
深圳翰宇药业股份有限公司
宓鹏程
C07K 14/605
Loading...
本发明涉及多肽合成领域，特别涉及一种替度鲁肽的聚乙二醇偶合物及其固相制备方法。本发明通过固相合成方法替度鲁肽对定点的PEG修饰，从而改变替度鲁肽的性质。其主要优点是可以延长蛋白质（多肽）在体内的半衰期，降低免疫原性和抗原性。
21. 106316888 一种手性氨基吡喃酮类化合物的合成方法
CN
11.01.2017
C07C 271/18 Loading...
C07C 271/18
Loading...
102015000367311
深圳翰宇药业股份有限公司
刘飞孟
C07C 271/18
Loading...
本发明涉及一种手性氨基吡喃酮类化合物的合成方法，以及该反应的中间产物N-Boc-1-(2,5-二氟苯基)-1-氧代-2-S-氨基戊-4炔的纯S手性构型，所述合成反应式为：
22. 106324153 测量氨基酸-N-甲酸酐含量和光学纯度的方法
CN
11.01.2017
G01N 30/06 Loading...
G01N 30/06
Loading...
102015000366664
深圳翰宇药业股份有限公司
李国弢
G01N 30/06
Loading...
本发明涉及一种测量氨基酸-N-甲酸酐含量和光学纯度的方法，该方法包括如下步骤，
23. 106310229 一种马昔瑞林薄膜衣片及其制备方法
CN
11.01.2017
A61K 38/22 Loading...
A61K 38/22
Loading...
102015000372393
深圳翰宇药业股份有限公司
郑春莲
A61K 38/22
Loading...
本发明提供一种马昔瑞林薄膜衣片，其包含马昔瑞林、填充剂、水溶性酸性固体辅料、崩解剂、润滑剂和包衣材料。相应地，本发明还提供制备本发明的马昔瑞林薄膜衣片的方法，包括以下步骤：(a)制备马昔瑞林颗粒；(b)压制素片；和(c)包衣。
24. 106309396 一种沃拉帕沙制剂的制备方法
CN
11.01.2017
A61K 9/28 Loading...
A61K 9/28
Loading...
201510369564.7
深圳翰宇药业股份有限公司
张伟明
A61K 9/28
Loading...
本发明涉及医药制剂领域，公开了一种沃拉帕沙制剂的制备方法。本发明所述制备方法将沃拉帕沙溶解后加入粘合剂制成溶液备用；填充剂和崩解剂进行流化混合，然后将前述制成的溶液喷洒到流化混合物中制粒并干燥，最后加入润滑剂混合均匀，压片，包衣，获得沃拉帕沙制剂。本发明通过一步制粒法减少了不必要的仪器和工艺步骤，将崩解剂和填充剂流化混合后，直接喷洒粘合剂和沃拉帕沙溶液制粒，所制备的沃拉帕沙制剂可压性高、药物含量均匀度好、药物释放充分和血药浓度高。
25. 106309384 一种注射用卡培立肽冻干组合物及其制备方法
CN
11.01.2017
A61K 9/19 Loading...
A61K 9/19
Loading...
102015000357639
深圳翰宇药业股份有限公司
徐春莲
A61K 9/19
Loading...
本发明涉及医药制剂领域，公开了一种注射用卡培立肽冻干组合物及其制备方法。本发明所述冻干组合物由主药卡培立肽、赋形剂和保护剂组成；所述赋形剂为乳糖、蔗糖、葡萄糖、氯化钠、山梨醇中的一种或两种以上；所述保护剂为甘氨酸、精氨酸、葡聚糖、PVP、木糖醇的一种或两种以上。本发明通过调整卡培立肽冻干组合物中的辅料，选择具有骨架赋形和保护作用的组分协同保护卡培立肽，使其能够在室温下甚至在高于25℃的极端环境下具有良好的稳定性，相比市售的卡培立肽粉针剂具有显著优势。
26. 106324113 试剂、试剂盒、应用及检测方法
CN
11.01.2017
G01N 30/02 Loading...
G01N 30/02
Loading...
102015000374239
深圳翰宇药业股份有限公司
潘远健
G01N 30/02
Loading...
本发明涉及生物检测领域，特别涉及试剂、试剂盒、应用及检测方法。本发明提供了硫代硫酸钠用于检测碘的应用。还提供了专属性强，灵敏度和回收率高，操作简便，浓度峰对称性好，干扰性小的离子色谱分析多肽药中氧化剂碘残留的方法。该方法能准确定量的供试品中含碘残留，能准确定量的浓度为50～1500ppm。供试品测得含碘残留量为300ppm，不超过规定限度(1000ppm)。
27. 106317161 一种氟甲基酮肽系列化合物的制备方法
CN
11.01.2017
C07K 1/06 Loading...
C07K 1/06
Loading...
102015000368626
深圳翰宇药业股份有限公司
陈学明
C07K 1/06
Loading...
本发明涉及一种氟甲基酮肽系列化合物的制备方法，所述制备方法包括如下步骤：步骤1)Fmoc-Asp(OR0)-OH制备Fmoc-Asp(OR0)-FMK；步骤2)将Fmoc-Asp(OR0)-FMK的侧链保护基R0脱除，得到侧链羧基裸露的Fmoc-Asp-FMK；步骤3)选用2-CTC树脂为固相载体合成Fmoc-Asp-FMK-CTC氨基酸树脂；步骤4)由Fmoc-Asp-FMK-CTC顺序偶联保护的氨基酸An，得到R1-An-Asp-FMK-CTC；步骤5)选用20％TFE/DCM的试剂将R1-An-Asp-FMK-CTC肽树脂进行切割得到全保护肽R1-An-Asp-FMK；步骤6)液相条件下，将R1-An-Asp-FMK中碳端Asp的侧链羧基进行修饰保护，得到全保护肽R1-An-Asp(OR2)-FMK；7)若肽序中除碳端Asp外的其他氨基酸有侧链保护基，则进行脱除保护基的裂解步骤。本发明的方法合成条件温和、工艺简单且工艺稳定。
28. 106316841 一种富马酸二甲酯的制备方法
CN
11.01.2017
C07C 67/08 Loading...
C07C 67/08
Loading...
102015000374849
深圳翰宇药业股份有限公司
陈新亮
C07C 67/08
Loading...
本发明涉及化学领域，特别涉及一种富马酸二甲酯的制备方法。该方法采用化学手段一步法控制BG-12原料药晶型和粒度的方法。该方法只需一个操作过程即可实现现有技术中重结晶和粉碎两个操作过程，得到符合制药生产要求的粒度，避免给操作者带来严重的刺激性反应，大大提高了生产安全性。该方法操作简便，参数容易控制，结果稳定，适用于大规模生产。通过调整该工艺的参数可以得到不同粒度范围的原料药，采用该操作过程可以避免粉碎带来的粉尘污染、清洁困难、过敏等现象。
29. 106317162 一种N-磷酰化多肽的制备方法
CN
11.01.2017
C07K 1/06 Loading...
C07K 1/06
Loading...
201510369451.7
深圳翰宇药业股份有限公司
陈学明
C07K 1/06
Loading...
本发明涉及一种N-磷酰化多肽的制备方法，该方法包括以下步骤：步骤1)准备固相合成用树脂；步骤2)用固相合成方法偶联Fmoc-AA-OH至固相合成树脂，加入脱保护剂A脱除Fmoc-保护后裸露氨基，并以此方法偶联多个氨基酸，获得NH2-An-固相合成用树脂；步骤3)在NH2-An-固相合成用树脂的末端氨基上偶联氯磷酸二酯；步骤4)用裂解液脱除步骤3)所得化合物的固相合成用树脂后获得磷酸二酯-NH-An-OH；步骤5)脱除二酯保护基；任选地，在步骤4)后纯化所得肽链和/或在步骤5)后纯化所得肽链；所述AA为氨基酸，所述An为由n个氨基酸组成的肽链，其中n≥2，且n为整数。本发明的制备方法操作简单、成本低、步骤少且收率有所提高。
30. 106316919 一种合成手性有机胺类化合物的方法
CN
11.01.2017
C07D 209/20 Loading...
C07D 209/20
Loading...
102015000366939
深圳翰宇药业股份有限公司
刘飞孟
C07D 209/20
Loading...
本发明属于生物医药领域，涉及一种合成手性有机胺类化合物的方法，其采用具有手性结构的芳香硝基化合物作为起始原料，与烯烃在有机铁化合物的催化下，在苯硅烷存在的反应体系中进行反应，尤其地，反应体系中存在还原金属和提供质子的弱酸性化合物。本发明首次针对具有手性结构的有机胺类化合物的合成，摸索出适合的反应体系，以阻止反应过程的消旋化反应，使得反应产物的手性纯度可达到高达99％以上。本发明的方法可以适用于合成含有高位阻的二级胺结构的非天然氨基酸，这具有极大的现实意义。
31. 106309399 一种微丸型缓释片及其制备方法
CN
11.01.2017
A61K 9/36 Loading...
A61K 9/36
Loading...
102015000368627
深圳翰宇药业股份有限公司
左灵静
A61K 9/36
Loading...
本发明涉及药物制剂领域，特别涉及一种微丸型缓释片及其制备方法。该含有美托洛尔盐和非洛地平的微丸型缓释片及其制备方法，能够有效降低压片时琥珀酸美托洛尔缓释微丸的包衣膜发生破裂的概率，因此能够提供压片前后非常接近的美托洛尔释放度，与市售制剂相比，还能够实现美托洛尔释放度的良好重现性。同时能够实现美托洛尔和非洛地平的同步24小时缓释效果。
32. 106279424 一种人甲状旁腺激素PTH(1-34)融合蛋白及其应用
CN
04.01.2017
C07K 19/00 Loading...
C07K 19/00
Loading...
102015000260555
深圳翰宇药业股份有限公司
康旭
C07K 19/00
Loading...
本发明属于医药生物工程技术领域，公开了一种人甲状旁腺激素PTH(1-34)融合蛋白及其在制备药物组合物中的应用，本发明将人IgG衍生的Fc区域连接于PTH(1-34)的C末端，从而有效延长了PTH(1-34)的循环半衰期和/或增加了其生物活性，克服了现有PTH(1-34)降解的问题，具备长效生物学活性，其蛋白表达量高，可用于工业化大规模生产。
33. 106290601 多肽药物中氨基酸消旋和非对映异构体杂质的检测方法
CN
04.01.2017
G01N 30/02 Loading...
G01N 30/02
Loading...
201510368588.0
深圳翰宇药业股份有限公司
何刚
G01N 30/02
Loading...
本发明涉及一种多肽药物合成中的氨基酸消旋以及非对映异构体杂质的检测方法，具体地，该检测方法是以离子交换色谱法对氨基酸消旋以及非对映异构体杂质进行检测。本发明的检测方法是基于氨基酸等电点差异，采用阳离子交换色谱法分析非对映异构体杂质，检测效率高，灵敏度高。
34. 104045705 一种利拉鲁肽的合成方法
CN
28.12.2016
C07K 14/605 Loading...
C07K 14/605
Loading...
102013000078238
深圳翰宇药业股份有限公司
陈友金
C07K 14/605
Loading...
本发明涉及多肽合成领域，特别涉及一种利拉鲁肽的合成方法。该方法通过依次将第三多肽片段、第二多肽片段、第一多肽片段与第四多肽片段‑树脂偶联，得到肽树脂，经侧链修饰、裂解、纯化、冻干，即得。本发明提供的利拉鲁肽的合成方法可提高粗肽的纯度和收率，有利于纯化，同时提高了产品的收率，缩短了合成时间，适合工业化生产。
35. 106137999 一种复方吡格列酮二甲双胍缓释片及其制备方法
CN
23.11.2016
A61K 9/28 Loading...
A61K 9/28
Loading...
102015000147969
深圳翰宇药业股份有限公司
刘慧
A61K 9/28
Loading...
本发明提供一种新的复方吡格列酮二甲双胍缓释制剂，其包括：含有盐酸二甲双胍的片芯；含乙基纤维素、致孔剂及增塑剂的微孔膜缓释层；包裹缓释片芯的隔离层；吡格列酮速释层；任选的密封包衣层。本发明还提供制备上述制剂的方法。
36. 106146648 一种甲状旁腺激素类似物的合成方法
CN
23.11.2016
C07K 14/635 Loading...
C07K 14/635
Loading...
102015000136475
深圳翰宇药业股份有限公司
肖庆
C07K 14/635
Loading...
本发明涉及医药合成领域，公开了一种甲状旁腺激素类似物的合成方法。本发明所述方法按照甲状旁腺激素类似物Abaloparatide肽链C端至N端的氨基酸顺序，合成1-15、16-23和24-33片段，然后再将这3个多肽片段偶联得到Abaloparatide，本发明多个片段合成同时进行，合成周期短，中间体易纯化，成本低，最终产品纯度高，产品总收率高，利于Abaloparatide的大规模生产。
37. 106153748 一种检测多肽中N,N-二异丙基碳二亚胺的方法
CN
23.11.2016
G01N 30/02 Loading...
G01N 30/02
Loading...
102015000148254
深圳翰宇药业股份有限公司
何雄风
G01N 30/02
Loading...
本发明属于药物分析化学领域，公开了一种检测多肽中N,N-二异丙基碳二亚胺的方法。本发明所述检测方法分别用pH≤5的溶液溶解待测多肽样品和N,N-二异丙基碳二亚胺对照品制得供试品溶液和对照品溶液；采用液相色谱与质谱联用的方法检测供试品溶液中N,N-二异丙基碳二亚胺含量。本发明所述检测方法以pH≤5的溶液溶解多肽样品，营造一个酸性环境，使得多肽中的DIC完全转化为其尿素衍生物。本发明所述检测方法操作简单，检测仪器和试剂普通，检测成本低；检测时间短；检测结果准确、明显，易于判断；检测灵敏度高，质谱检测的检测限可以达到0.8ppm，广泛适合于多肽类药物中DIC的检测。
38. 106146360 一种制备酪氨酸-O-磺酸盐的方法
CN
23.11.2016
C07C 305/24 Loading...
C07C 305/24
Loading...
102015000147405
深圳翰宇药业股份有限公司
刘飞孟
C07C 305/24
Loading...
本发明涉及一种制备酪氨酸-O-磺酸盐的方法，其包括如下步骤：(1)在稀释剂和碱的存在下，将磺化试剂和Fmoc保护的酪氨酸反应，得到反应液；(2)将步骤(1)的反应液倒入不良溶剂中，然后静置；(3)倾去步骤(2)所得物的上清液，残余物用水溶解，然后用碱调节pH至弱酸性；(4)用良溶剂洗涤步骤(3)所得水溶液，然后浓缩；(5)向步骤(4)的浓缩物中加入良溶剂并搅拌，过滤，滤液加入至不良溶剂中，搅拌，收集固体，干燥，得到固体；所述方法避免了使用蒸馏、冻干等耗时长、设备要求高的问题，后处理中通过增加萃取操作，极大地提高了纯度，避免了使用难以放大的柱层析纯化操作，其是一个适合放大生产、操作简单、产品纯度高的方法。
39. 106137979 一种冻干粉针剂及其制备方法
CN
23.11.2016
A61K 9/19 Loading...
A61K 9/19
Loading...
102015000147399
深圳翰宇药业股份有限公司
郑春莲
A61K 9/19
Loading...
本发明涉及药物制剂领域，特别涉及一种冻干粉针剂及其制备方法。本发明提供的velcalcetide冻干粉针剂质量好、提高了velcalcetide的稳定性，使该药物制剂可以在室温下长期放置。在注射用水、0.9％氯化钠注射液或5％葡萄糖注射液中能迅速溶解，溶解后溶液无色澄清、无杂质沉淀、组织相容性良好，更有利于velcalcetide的推广和使用。此外，本发明的冻干工艺能有效的解决在冻干过程中的破瓶现象，冻干后无破瓶。本发明提供的冻干粉针剂没有成品分层和萎缩现象，提高成品收率。
40. 106137980 一种罗米地辛脂微球制剂及其制备方法
CN
23.11.2016
A61K 9/19 Loading...
A61K 9/19
Loading...
102015000148655
深圳翰宇药业股份有限公司
颜携国
A61K 9/19
Loading...
本申请涉及一种罗米地辛脂微球制剂及其制备方法。其可包含罗米地辛、注射用油、乳化剂、稳定剂、等渗调节剂、pH调节剂和注射用水。本发明的罗米地辛脂微球制剂具有良好的稳定性和缓释特性，提高了罗米地辛的靶向性，降低了其毒副作用。
41. 106146510 一种维格列汀降解杂质的制备方法
CN
23.11.2016
C07D 487/04 Loading...
C07D 487/04
Loading...
102015000149715
深圳翰宇药业股份有限公司
刘飞孟
C07D 487/04
Loading...
本发明涉及化工技术领域，公开了一种维格列汀降解杂质的制备方法。本发明所述制备方法将维格列汀与化合物1、化合物2反应生成N-(3-羟基金刚烷)-1-亚氨基-六氢吡咯并[1,2-a]吡嗪-4(1H)-酮；所述化合物1为乙酸乙酯或甲苯，所述化合物2为三乙胺或二异丙基乙基胺。本发明以维格列汀为原料，选择适宜的反应物进行其降解产物的制备，工艺简便，收率和纯度较高，为控制维格列汀药物制品的质量标准提供了基础。
42. WO/2016/172855 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR POLYPEPTIDE MIXTURES
WO
03.11.2016
C07K 2/00 Loading...
C07K 2/00
Loading...
PCT/CN2015/077690
HYBIO PHARMACEUTICAL CO., LTD.
TANG, Yangming
C07K 2/00
Loading...
Provided is a high performance liquid chromatography method for polypeptide mixtures. Specifically, the method comprises the following steps of (1) formulating a Glatiramer acetate solution to be tested; (2) subjecting the sample to be tested to gradient elution by way of anion exchange liquid chromatography, cation exchange liquid chromatography or reversed-phase liquid chromatography; and (3) detecting and analyzing peak areas corresponding to various components of the copolymer, and by means of comparison with a control, determining whether the content ranges of the various components in the sample to be tested are qualified.
43. 105884763 一种阿哌沙班的纯化方法
CN
24.08.2016
C07D 471/04 Loading...
C07D 471/04
Loading...
102014000505909
深圳翰宇药业股份有限公司
肖庆
C07D 471/04
Loading...
本发明涉及一种阿哌沙班的纯化方法，包括：步骤1：常温脱色用溶剂溶解未经纯化的阿哌沙班，并加入活性炭作为脱色剂，在常温下进行脱色，得到精制的阿哌沙班，其中，为实现常温脱色，溶剂选择C1‑C5醇类或二甲基甲酰胺，步骤2：中速搅拌转晶型将脱色后的精制的阿哌沙班用C1‑C5醇类重结晶，降温析晶时中速搅拌即可得到阿哌沙班的N‑1无溶剂晶型。
44. 105884669 制备取代的(S)-吡咯烷-2-甲腈及维格列汀的方法
CN
24.08.2016
C07D 207/16 Loading...
C07D 207/16
Loading...
102014000466764
深圳翰宇药业股份有限公司
刘飞孟
C07D 207/16
Loading...
本发明提供一种制备下式(I)的(S)‑1‑(2‑卤乙酰基)吡咯烷‑2‑甲腈的方法，包括任选在稀释剂存在下，用式(IV)的(S)‑1‑(2‑卤乙酰基)吡咯烷‑2‑甲酰胺与脱水剂丙基磷酸酐(T3P)反应；还提供一种包括前述反应的、以S‑脯氨酰胺为原料制备维格列汀的方法。使用所述方法制备化合物式(I)具有下优势：无需使用价格高昂的三氟乙酸酐，提高了产率，降低了成本；无需使用由剧毒原料制备的三聚氯氰，使反应更加环保；从而获得一种改进的制备维格列汀的方法。其中，X1为卤素。
45. 103417506 一种别嘌醇缓释微丸及其制备方法和制剂
CN
10.08.2016
A61K 9/22 Loading...
A61K 9/22
Loading...
102013000253637
深圳翰宇药业股份有限公司
左灵静
A61K 9/22
Loading...
本发明涉及医药技术领域，尤其涉及一种别嘌醇缓释微丸及其制备方法和制剂。该别嘌醇缓释微丸包括别嘌醇和阴离子聚合物，其中，各组分的含量以质量份计为：别嘌醇30份～95份、阴离子聚合物1份～20份。本发明提供的别嘌醇缓释微丸中还可以包括稀释剂或丸芯。该别嘌醇缓释微丸将阴离子聚合物同时作为粘合剂和缓释材料使用，不需要额外的粘合剂，从而减少了辅料的种类和用量，提高了微丸中别嘌醇的相对含量。另外，将阴离子聚合物应用在微丸骨架中，也略去了缓释材料包衣的步骤，从而减少了制备步骤。因此，本发明提供的别嘌醇缓释微丸在简化了配方的同时也简化了制备工艺。
46. 104055735 一种萨摩鲁泰的脂质体及其制备方法
CN
03.08.2016
A61K 9/127 Loading...
A61K 9/127
Loading...
102013000093730
深圳翰宇药业股份有限公司
徐春莲
A61K 9/127
Loading...
本发明涉及医药技术领域，尤其涉及一种萨摩鲁泰的脂质体及其制备方法。本发明提供的萨摩鲁泰脂质体，包括：磷脂、萨摩鲁泰、胆固醇和药学上可接受的冷冻保护剂，粒径为50nm～200nm。本发明提供的萨摩鲁泰脂质体以磷脂和胆固醇为膜材料，将萨摩鲁泰包裹其中，形成带有负电荷的脂质体。从而降低了萨摩鲁泰对胰腺和肾脏的损伤、减轻了服用萨摩鲁泰后的胃肠道反应，并提高了萨摩鲁泰的稳定性和生物利用度。
47. 105796522 含糠酸氟替卡松和维兰特罗的脉冲控释片及制备方法
CN
27.07.2016
A61K 9/28 Loading...
A61K 9/28
Loading...
201410841069.7
深圳翰宇药业股份有限公司
郑春莲
A61K 9/28
Loading...
本发明提供了一种糠酸氟替卡松和维兰特罗的脉冲控释片，该脉冲控释片能在半夜和清晨到达血药浓度，从而达到时辰治疗的目的。所述的脉冲控释片包括漂浮层和片芯两个部分。漂浮层采用亲水性高分子和脂肪醇为辅料,使其在胃内能滞留一定的时间.药片与胃液接触时,漂浮层表面水化形成凝胶使体积膨胀,当小于胃液密度时,便漂悬于胃内容物内,随着漂浮层的骨架溶蚀,露出片芯,从而使药物从片芯释放出来。
48. 105801439 一种制备O-去甲文拉法辛的方法
CN
27.07.2016
C07C 215/64 Loading...
C07C 215/64
Loading...
201410840720.9
深圳翰宇药业股份有限公司
袁慧星
C07C 215/64
Loading...
本发明提供一种制备O-去甲文拉法辛或其可药用盐的方法，包括使1-[1-(4-苄氧基苯基)-2-(二甲胺基)乙基]-环己醇在惰性溶剂中与金属硫化物反应，从而形成O-去甲文拉法辛。反应条件温和，反应时间明显缩短，后处理简单，并且所用原料价格低廉且安全性高，利于工业化生产。
49. 105796503 一种沙格列汀微丸及其制剂
CN
27.07.2016
A61K 9/16 Loading...
A61K 9/16
Loading...
201410853504.8
深圳翰宇药业股份有限公司
张伟明
A61K 9/16
Loading...
本发明涉及药物制剂领域，特别涉及一种沙格列汀微丸及其制剂。该沙格列汀微丸从内到外依次由丸芯、第一隔离层、含药层和第二隔离层组成；第二隔离层含有包衣材料，包衣材料为尤特奇或乙基纤维素。本发明提供的微丸稳定性提高，有关物质含量增长较慢，耐贮存；本发明提供的微丸具有很好的缓释效果，服用后既可使血药浓度迅速达到治疗效果，又能维持较长作用时间，血药浓度平稳，重现性好，不良反应发生率低；本发明提供的微丸生产时便于控制质量，外形美观，流动性好，粉尘少。
50. 105777732 一种利伐沙班中间体的合成方法及其应用
CN
20.07.2016
C07D 413/10 Loading...
C07D 413/10
Loading...
201410778926.3
深圳翰宇药业股份有限公司
袁慧星
C07D 413/10
Loading...
本发明属于药物合成技术领域，公开了一种合成利伐沙班中间体B的方法，该方法在反应溶剂甲苯中，在脱保护试剂乙醇胺的作用下，将原料A中的邻苯二甲酰亚胺保护基脱除，并经后处理后，获得中间体B。同时，本发明还公开了本发明所述的合成利伐沙班中间体B的方法在制备利伐沙班中的应用。与现有的合成利伐沙班的路线相比，本发明采用4-(4-碘苯基)-3-吗啉酮与N-(3-氨基-2-羟基异丙基)邻苯二甲酰亚胺缩合关环，再使用乙醇胺溶液脱除邻苯二甲酰亚胺保护基，避免了甲胺溶液和肼的使用，从而避免了使用甲胺溶液或肼所造成的毒副作用，环境友好，且收率较高。
51. 105777872 一种萨摩鲁肽的纯化方法
CN
20.07.2016
C07K 14/00 Loading...
C07K 14/00
Loading...
201410784130.9
深圳翰宇药业股份有限公司
尹传龙
C07K 14/00
Loading...
本发明属于药物化学技术领域，公开了一种萨摩鲁肽的纯化方法。该纯化方法包括：取待纯化的萨摩鲁肽样品，经化学键合硅胶色谱柱第一分离，以A1溶液与B溶液的混合溶液进行梯度洗脱，收集洗脱组分，得第一次纯化物；取第一次纯化物，经化学键合硅胶色谱柱第二分离，以A2溶液与B溶液的混合溶液进行梯度洗脱，收集洗脱组分，得萨摩鲁肽溶液；A1溶液为碳酸盐溶液；A2溶液为磷酸盐溶液；B溶液为乙腈和异丙醇的混合溶液，乙腈与异丙醇的体积之比为(8:2)～(9:1)。该纯化方法制备获得的萨摩鲁肽纯度高，显著提高了萨摩鲁肽的收率，且操作简单，有利于实现萨摩鲁肽的规模化制备。
52. 105777892 普兰林肽聚乙二醇衍生物、其制备方法及其应用
CN
20.07.2016
C07K 14/575 Loading...
C07K 14/575
Loading...
201410786855.1
深圳翰宇药业股份有限公司
康旭
C07K 14/575
Loading...
本发明属于药物合成技术领域，公开了一种普兰林肽聚乙二醇衍生物，其由普兰林肽和与普兰林肽共价连接的聚乙二醇组成，聚乙二醇在普兰林肽的N端进行修饰，普兰林肽的N端可以连接在聚乙二醇的一个末端或两个末端。同时，本发明还公开了制备本发明普兰林肽聚乙二醇衍生物的方法以及该衍生物在制备用于治疗糖尿病的药物制剂中的应用。与现有制剂形式相比，本发明的普兰林肽聚乙二醇衍生物提高了普兰林肽在体内的半衰期，并且药效实验证明，本发明的普兰林肽聚乙二醇衍生物与胰岛素联合使用降糖维持时间与未经PEG修饰的普兰林肽相比，得到明显延长。
53. 105753964 一种萨摩鲁肽的制备方法及其中间体
CN
13.07.2016
C07K 14/605 Loading...
C07K 14/605
Loading...
102014000784161
深圳翰宇药业股份有限公司
陈永汉
C07K 14/605
Loading...
本发明属于药物化学技术领域，公开了一种萨摩鲁肽的制备方法及其中间体。该制备方法包括：获得具有式I所示结构的化合物；取树脂，活化后，逐步偶联L-甘氨酸、L-精氨酸、L-甘氨酸、L-精氨酸、L-缬氨酸、L-亮氨酸、L-色氨酸、L-丙氨酸、L-异亮氨酸、L-苯丙氨酸、L-谷氨酸、具有式I所示结构的化合物，得第一肽树脂；取第一肽树脂，逐步偶联氨基酸或氨基酸衍生物得到第二肽树脂；取第二肽树脂，经裂解、纯化，即得。该方法以具有式I所示结构的化合物作为中间体，采用固相合成法逐步偶联各个氨基酸或氨基酸衍生物，显著提高了萨摩鲁肽的收率；R1选自Fmoc、Boc、ivDde；R2选自tBu、Dmab、Bzl。
54. 105713082 一种制备利西拉来的方法
CN
29.06.2016
C07K 14/575 Loading...
C07K 14/575
Loading...
201410733667.2
深圳翰宇药业股份有限公司
张文治
C07K 14/575
Loading...
本发明涉及一种制备利西拉来的方法，采用片段缩合方法合成利西拉来，具体采用片段20-44肽树脂与片段15-19进行固相缩合，然后逐步偶联剩余氨基酸至固相合成结束。与常规的逐步偶联相比，提高了粗肽纯度和纯化收率。
55. 105717203 一种利拉鲁肽中游离棕榈酸的检测方法
CN
29.06.2016
G01N 30/02 Loading...
G01N 30/02
Loading...
102014000720052
深圳翰宇药业股份有限公司
张雷
G01N 30/02
Loading...
本发明属于药物合成技术领域，公开了一种利拉鲁肽中游离棕榈酸的检测方法，该方法在对利拉鲁肽中的游离棕榈酸进行高效液相色谱分析过程中，采用电喷雾检测器进行检测，具有专属性好(检测无干扰)、灵敏度高(检测限为2.05ng)、稳定性高(精密度高)、方法可靠(回收率大于90％)等优点，非常适合于对利拉鲁肽中游离棕榈酸的准确测量。
56. 103275207 一种制备奈西立肽的方法
CN
22.06.2016
C07K 14/58 Loading...
C07K 14/58
Loading...
102013000094866
深圳翰宇药业股份有限公司
肖庆
C07K 14/58
Loading...
本发明涉及一种制备奈西立肽的方法，其操作简单、成本低、制备周期短和/或总收率高（＞25%），有利于大规模生产。所述制备奈西立肽的方法包括：制备5个片段，将所述片段依次偶联得到线型奈西立肽，然后经氧化得到奈西立肽，所述方法任选地包括纯化奈西立肽的步骤。
57. 103204923 固相片段法制备卡培立肽
CN
22.06.2016
C07K 14/58 Loading...
C07K 14/58
Loading...
102013000093066
深圳翰宇药业股份有限公司
张文治
C07K 14/58
Loading...
本发明公开了一种采用Fmoc路线固液结合片段法合成卡培立肽的方法，该方法中多个片段合成同时进行，合成周期减少了2/3，中间体易纯化，成本低，最终产品纯度高，副产物少，产品收率高，利于卡培立肽的大规模生产，使用本发明的方法得到的粗肽纯度为75%以上，总收率达到25%以上。
58. 105651914 一种直接测定SGLT2抑制剂共晶体中手性共晶溶剂的方法
CN
08.06.2016
G01N 30/88 Loading...
G01N 30/88
Loading...
201410719946.3
深圳翰宇药业股份有限公司
黄俊
G01N 30/88
Loading...
本发明属于药物合成技术领域，公开了一种直接测定SGLT2抑制剂共晶体中手性共晶溶剂含量的方法，其采用手性气相色谱分析的方法，直接对SGLT2抑制剂共晶体中手性共晶溶剂的含量进行测定。与现有的柱前衍生方法相比，本发明的方法具有简便、快速和准确的优点，并且避免了使用昂贵且毒性较大的衍生试剂以及气相色谱所带来的严重污染。
59. WO/2016/045646 PREPARATION METHOD FOR GLATIRAMER ACETATE
WO
31.03.2016
C07K 14/00 Loading...
C07K 14/00
Loading...
PCT/CN2015/095606
HYBIO PHARMACEUTICAL CO., LTD.
YUAN, Huixing
C07K 14/00
Loading...
Provided is a method for the preparation of glatiramer acetate, comprising: (1) dissolving L-alanine NCA, L-tyrosine NCA, L-glutamic acid-γ-benzyl ester NCA and L-ε-trifluoroacetyl-lysine NCA in a 1,4-dioxane solvent, and stirring until the system is clear; (2) adding diethylamine, stirring at 20-25°C, then slowing pouring the reaction solution into water, and obtaining white product; (3) adding the obtained product to a hydrobromic-acetic acid solution, stirring at 23.0-25.0°C, pouring the reaction solution into purified water after stirring for quenching, stirring, performing suction filtration to obtain a yellow solid, and after repeating 3-5 times, performing drying; (4) dissolving the solid with a 1M piperidine solution at room temperature and stirring, and after the obtained solution has undergone dialysis, adding glacial acetic acid to adjust the pH to be 5.5-7.0, and performing lyophilisation.
60. 105440025 一种制备卡格列净及其中间体的方法及所述中间体
CN
30.03.2016
C07D 409/10 Loading...
C07D 409/10
Loading...
201410499537.7
深圳翰宇药业股份有限公司
陈新亮
C07D 409/10
Loading...
本申请属于药物领域，尤其涉及一种制备卡格列净及其中间体的方法及所述中间体。本申请提供的卡格列净的制备方法，包括以下步骤：式(I)所示结构化合物进行脱苄基反应，得到卡格列净。本申请提供的制备方法反应路线简单，中间体无需纯化，制品纯度和收率高。实验结果表明，采用本申请提供的方法制备卡格列净时，产品收率大于88％，纯度大于99.5％。
61. 105412904 利那洛肽肠溶缓释微丸胶囊制剂及其制备方法和用途
CN
23.03.2016
A61K 38/10 Loading...
A61K 38/10
Loading...
201410269883.6
深圳翰宇药业股份有限公司
徐春莲
A61K 38/10
Loading...
本申请涉及一种利那洛肽肠溶缓释微丸胶囊制剂，其由利那洛肽肠溶缓释微丸和空心胶囊组成，其中所述利那洛肽肠溶缓释微丸包括含药丸芯、隔离层、缓释层和肠溶层。本申请还涉及一种制备利那洛肽肠溶缓释微丸胶囊制剂的方法及利那洛肽肠溶缓释微丸胶囊制剂用于制备治疗便秘型肠易激综合征的药物的用途。
62. 105330720 一种制备马昔瑞林的方法
CN
17.02.2016
C07K 5/062 Loading...
C07K 5/062
Loading...
201410250544.3
深圳翰宇药业股份有限公司
陈永汉
C07K 5/062
Loading...
本发明涉及一种制备马昔瑞林的方法，更具体地，涉及一种固相合成马昔瑞林的方法。
63. 105273022 一种索非布韦中间体以及由其制备索非布韦的方法
CN
27.01.2016
C07H 19/073 Loading...
C07H 19/073
Loading...
201410268388.3
深圳翰宇药业股份有限公司
李国弢
C07H 19/073
Loading...
本发明涉及药物合成技术领域，具体公开了制备索非布韦的式VI所示的化合物及其制备方法，同时本发明还公开了由上述化合物制备索非布韦的方法。在本发明制备索非布韦的方法中，只采用一个保护基，既提高了伯醇、仲醇的选择性，又不会浪费大量的化工原料，实现了绿色化学的基本理念。同时，本发明制备索非布韦的方法又避免了产生不必要的杂质，反应的选择性高，副产物少，进一步增加了原子的经济性。
64. 105267156 一种帕西瑞肽冻干粉针剂及其制备方法
CN
27.01.2016
A61K 9/19 Loading...
A61K 9/19
Loading...
201410283755.7
深圳翰宇药业股份有限公司
郑春莲
A61K 9/19
Loading...
本发明属于药物制剂技术领域，公开了一种帕西瑞肽冻干粉针剂及其制备方法。本发明提供的帕西瑞肽冻干粉针剂由帕西瑞肽、赋形剂、稳定剂、pH值调节剂和注射用水冻干制成。该帕西瑞肽冻干粉针剂质量好、对光稳定，可以在室温下长期放置，在注射用水、0.9％氯化钠注射液或5％葡萄糖注射液中能迅速溶解，溶解后溶液无色澄清、无杂质沉淀、组织相容性良好、更有利于帕西瑞肽的推广和使用。
65. 105223281 一种用于检测卡帕松制剂中醋酸格拉替雷浓度的色谱方法
CN
06.01.2016
G01N 30/02 Loading...
G01N 30/02
Loading...
201410289379.2
深圳翰宇药业股份有限公司
唐洋明
G01N 30/02
Loading...
一种用于检测卡帕松制剂中醋酸格拉替雷浓度的色谱方法。本发明涉及一种采用Thermo？scientific？Dionex液相色谱仪的Corona？CAD电喷雾检测器，及专属于该型号检测设备的HPLC色谱条件，用于检测含有甘露醇辅料的醋酸格拉替雷样品(即市售卡帕松制剂)中的醋酸格拉替雷浓度。
66. 105218646 一种用于检测醋酸格拉替雷样本的UPLC方法
CN
06.01.2016
C07K 14/00 Loading...
C07K 14/00
Loading...
201410290469.3
深圳翰宇药业股份有限公司
唐洋明
C07K 14/00
Loading...
本发明提供一组与醋酸格拉替雷(共聚物-1)结构相似的内标肽作为共聚物-1分子量测定用内标以及与其配套使用的UPLC检测及分离参数，使用方法能够在高分辨的UPLC分离技术下，更准确的测定目标聚合物的分子量及分子量分布。
67. 105218515 一种药用来那度胺半水合物晶体的制备方法
CN
06.01.2016
C07D 401/04 Loading...
C07D 401/04
Loading...
201410290468.9
深圳翰宇药业股份有限公司
陈新亮
C07D 401/04
Loading...
本发明涉及一种从来那度胺粗品出发，重结晶制备药用来那度胺半水合物晶体的方法。采用混合溶剂和水进行重结晶，通过控制降温速率和水的量可以很好的得到用于符合制剂要求的半水合结晶产物；所述的混合溶剂体系是甲醇、1，4-二氧六环，N,N-二甲基甲酰胺、乙腈、乙醇、N-甲基吡咯烷酮、异丙醇、丙酮、乙醚、二氯甲烷等两组分和多组分的混合溶剂。
68. 105175406 HCV抑制剂的中间体以及由其制备HCV抑制剂的方法
CN
23.12.2015
C07D 417/04 Loading...
C07D 417/04
Loading...
201410253888.X
深圳翰宇药业股份有限公司
李国弢
C07D 417/04
Loading...
本发明涉及药物合成技术领域，具体公开了制备HCV抑制剂Simeprevir的如式IV和式V所示的化合物及其制备方法，同时本发明还公开了由上述化合物制备HCV抑制剂Simeprevir的方法。在制备HCV抑制剂Simeprevir的过程中，本发明在合成14元大环时采用酰胺化反应替代了现有的复分解反应，而酰胺化反应的效率比复分解反应要高的多，合成烯烃的步骤提前进行，这样在合成过程中不仅大大缩短了整个合成的反应步骤，操作简单，并且还不必消耗昂贵的羟基环戊二酸和杂环酚，从而大大降低了生产成本。
69. WO/2015/188774 GANIRELIX PRECURSOR AND METHOD FOR PREPARING GANIRELIX ACETATE BY USING ANIRELIX PRECURSOR
WO
17.12.2015
C07K 7/23 Loading...
C07K 7/23
Loading...
PCT/CN2015/081311
HYBIO PHARMACEUTICAL CO., LTD.
CHEN, Youjin
C07K 7/23
Loading...
Disclosed is a method for preparing ganirelix acetate. The method comprises the following steps: respectively replacing Fmoc-HArg(Et) 2-OH and Fmoc-D-HArg(Et) 2-OH by employing Fmoc-Lys(Boc)-OH and Fmoc-D-Lys(Boc)-OH or Fmoc-Lys(Alloc)-OH and Fmoc-D-Lys(Alloc)-OH; synthesizing a ganirelix precursor I or ganirelix precursor II-peptide resin in advance; and then respectively performing modifications and treatments on side chain amino groups of Lys and D-Lys in the precursor I or the precursor II-peptide resin to obtain ganirelix acetate. The ganirelix acetate synthesized therefrom is high in purity, has less impurities and a relatively low in cost, and is suitable for large-scale production.
70. 104447374 Preparation method of sitagliptin and intermediate thereof
CN
25.03.2015
C07C 229/34 Loading...
C07C 229/34
Loading...
201310425340.4
深圳翰宇药业股份有限公司
姚志军
C07C 229/34
Loading...
The invention relates to the field of medicament synthesis and especially relates to a preparation method of sitagliptin and an intermediate thereof. The preparation method is as below: in the presence of a first organic solvent, a compound shown as formula I and a compound shown as formula II conduct reductive amination reaction under the action of sodium triacetoxyborohydride and lewis acid, so as to obtain a compound shown in formula III. The preparation method provided by the invention does not use precious metal as the catalyst, reduces the cost, simplifies the process, increases the yield, and improves the chemical purity and optical purity of sitagliptin. R1 represents C1-6 alkyl, C1-6 alkyl substituted alkyl or benzyl, R2 represents methyl or carbamoyl, and Ar represents phenyl, monosubstituted phenyl or polysubstituted phenyl.
71. WO/2015/027893 DABIGATRAN ETEXILATE SYNTHESIZING METHOD
WO
05.03.2015
C07D 401/12 Loading...
C07D 401/12
Loading...
PCT/CN2014/085156
HYBIO PHARMACEUTICAL CO., LTD.
CHEN, Xinliang
C07D 401/12
Loading...
The present invention relates to a dabigatran etexilate synthesizing method, the method being characterized by: using 2-(hydroxymethyl)-1H-benzimidazole -5-carboxy acid as raw material, thus greatly reducing the raw material and reagent costs for synthesizing benzimidazole, and having considerable economic value and market competitiveness; and not discharging a great deal of waste acid in a reaction process, thus having environmental value, and providing an optimal solution for large-scale industrial production of dabigatran etexilate.
72. WO/2015/021904 METHOD FOR SYNTHESIZING GLATIRAMER ACETATE
WO
19.02.2015
C07K 14/00 Loading...
C07K 14/00
Loading...
PCT/CN2014/084164
HYBIO PHARMACEUTICAL CO., LTD.
LI, Guotao
C07K 14/00
Loading...
Disclosed is a method for synthesizing glatiramer acetate. The present method uses two or multiple depolymerization steps to control the average molecular weight of the glatiramer acetate product within a relatively narrow range.
73. WO/2014/206210 METHOD FOR PREPARING EPTIFIBATIDE
WO
31.12.2014
C07K 7/06 Loading...
C07K 7/06
Loading...
PCT/CN2014/079935
HYBIO PHARMACEUTICAL CO., LTD.
KANG, Xu
C07K 7/06
Loading...
Provided is a method for preparing eptifibatide, wherein the method comprises: obtaining an eptifibatide refined peptide solution; and obtaining and freeze-drying an eptifibatide refined peptide concentrate after rotary evaporation of the eptifibatide refined peptide solution, wherein the concentration of the eptifibatide refined peptide concentrate is 15-30 mg/ml and the temperature of rotary evaporation is 251°C-35°C. The preparation method of the eptifibatide refined peptide solution is as follows: coupling Cys with a resin to obtain a Cys-resin; obtaining a polypeptide having a sequence as represented by SEQ ID NO: 1 by gradually coupling the Cys-resin with Pro, Trp, Asp, Gly, Har and Mpr; and obtaining the eptifibatide refined peptide solution through oxidation, cleavage, purification and transfer to salt.
74. 104231059 Polypeptide as well as preparation method and use thereof
CN
24.12.2014
C07K 14/00 Loading...
C07K 14/00
Loading...
201310243117.8
深圳翰宇药业股份有限公司
戴政清
C07K 14/00
Loading...
The invention relates to the field of polypeptide synthesis and particularly relates to a polypeptide as well as a preparation method and use thereof. The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1, and the terminal N of the polypeptide is acetylated. From the terminal N, amido bond cyclization is carried out on an X8 main chain at the 22nd site and an X9 side chain at the 25th site in the polypeptide. The polypeptide after amido bond cyclization provided by the invention retains the biological activity of Astressin B, is high in metabolic stability and can be used for effectively preventing and treating alopecia. The preparation method of the polypeptide has the advantages of low production cost and high yield.
75. WO/2014/187302 DULAGLUTIDE INJECTION AND PREPARATION METHOD THEREOF
WO
27.11.2014
A61K 38/26 Loading...
A61K 38/26
Loading...
PCT/CN2014/077845
HYBIO PHARMACEUTICAL CO., LTD.
WANG, Bo
A61K 38/26
Loading...
Disclosed are a dulaglutide injection and the preparation method thereof, the injection containing: dulaglutide, a pH regulator, a solubilizer, an antimicrobial agent, an osmotic pressure regulator, and water for injection, wherein, in addition to water for injection, the content of each component by weight ratio is: dulaglutide:the pH regulator:the solubilizer:the antimicrobial agent: the osmotic pressure regulator 1.5:(2.0-35):(2-5): 7-16:(180-420), and the ratio of the total weight of these five components and the volume of the water for injection in mg/ml is 0.6-1.6.
76. 104016975 Preparation method of rivaroxaban
CN
03.09.2014
C07D 413/14 Loading...
C07D 413/14
Loading...
201410301323.4
深圳翰宇药业股份有限公司
袁慧星
C07D 413/14
Loading...
The invention provides a preparation method of rivaroxaban, which uses 4-(4-iodophenyl)-3-morpholone and (S)-(+)-N-(3-amino-2-hydroxyisopropyl)phthalimide as initial raw materials. The synthesis route is simple, the reaction conditions in each reaction are mild, and the product is easy to separate; and thus, the reaction yield is high, the product purity is high, and the method can be used for industrial production.
77. 103990115 Nesiritide pharmaceutical composition, preparing method thereof and preparations thereof
CN
20.08.2014
A61K 38/22 Loading...
A61K 38/22
Loading...
201410196509.8
深圳翰宇药业股份有限公司
颜携国
A61K 38/22
Loading...
The invention relates to the field of pharmaceutical preparations, and particularly relates to a nesiritide pharmaceutical composition, a preparing method thereof and preparations thereof. The preparing method includes: mixing pharmaceutically acceptable salts of nesiritide, a freeze-dried excipient and a pH conditioning agent to obtain a nesiritide solution, and subjecting the nesiritide solution to a first cooling step, a heating step and a second cooling step. The nesiritide pharmaceutical composition prepared by the method is good in stability and is obviously superior to products in the market at present.
78. 103936822 Synthesis method of lisinopril
CN
23.07.2014
C07K 5/068 Loading...
C07K 5/068
Loading...
201410199474.3
深圳翰宇药业股份有限公司
陈友金
C07K 5/068
Loading...
The invention relates to the field of medicine synthesis, particularly a synthesis method of lisinopril. The synthesis method comprises the following steps: coupling Pro with a resin, and removing the amino protective group to obtain an H-Pro-resin; coupling Lys with the H-Pro-resin to obtain an Lys-Pro-resin; removing the amino protective group of the Lys-Pro-resin to obtain an H-Lys-Pro-resin; in the presence of a solvent, carrying out reduction amination reaction on the H-Lys-Pro-resin and 2-oxo-4-phenylbutyric acid to obtain a lisinopril precursor-resin; and taking the lisinopril precursor-resin, cracking and removing the protective group to obtain the lisinopril. The synthesis method can greatly enhance the lisinopril yield, simplifies the operation steps, shortens the synthesis period, and has high safe operation coefficient.
79. 203710378 一种制备胸腺法新原位凝胶植入剂的系统
CN
16.07.2014
A61J 3/00 Loading...
A61J 3/00
Loading...
201420063682.6
深圳翰宇药业股份有限公司
颜携国
A61J 3/00
Loading...
本实用新型涉及一种制备胸腺法新原位凝胶植入剂的系统，包括凝胶获得装置、凝胶除菌装置以及凝胶储备装置，凝胶获得装置包括投料口、呼吸口、溶剂导入口、搅拌桨、内腔、温度控制层以及带阀门的放液口；凝胶除菌装置包括离心泵以及除菌处理装置；凝胶储备装置包括带阀门的入口、带阀门的放液口、温度控制层、内腔以及清洗口。凝胶获得装置下部的放液口与凝胶除菌装置的离心泵连通，离心泵的出口与除菌处理装置连通，除菌处理装置与凝胶储备装置的带阀门的入口连通。本实用新型公开的系统实现了制备胸腺法新原位凝胶制剂的流程化和自动化，大大提高了制备胸腺法新原位凝胶制剂的效率，可有效节约成本。
80. WO/2014/101828 METHOD FOR PREPARING ROMIDEPSIN
WO
03.07.2014
C07K 5/12 Loading...
C07K 5/12
Loading...
PCT/CN2013/090669
HYBIO PHARMACEUTICAL CO.,LTD.
XIAO, Qing
C07K 5/12
Loading...
Disclosed is a method for preparing Romidepsin. The present invention relates to the pharmaceutical synthesis. The present invention is based on a method of solid phase synthesis. First, coupling is performed between resin and carboxyl groups on 3-hydroxy-7-mercapto-4-heptenoic acid; then,coupling is performed in sequence between four pieces of amino acid on Romidepsin; then, hydroxyl groups are removed, and disulfide bonds and amido bonds are obtained by means of cyclization, so as to form Romidepsin. The purity the finally finished product is greater than 99%, the total yield is higher than 30%, and method features simple preparation, a short synthesis cycle and low cost, and helps to produce Romidepsin in a large scale.
81. 103897029 Preparation method for romidepsin
CN
02.07.2014
C07K 5/10 Loading...
C07K 5/10
Loading...
201210579007.4
深圳翰宇药业股份有限公司
肖庆
C07K 5/10
Loading...
The invention relates to the field of medicine synthesis and discloses a preparation method for romidepsin. The preparation method is based on a solid-phase synthesis process and comprises the following steps: coupling a resin with a carboxyl group on 3-hydroxy-7-mercapto-4-heptenoic acid; then coupling four amino acids on romidepsin in sequence; and then removing the carboxyl group and carrying out cyclization to form a disulfide bond and an amide bond, thereby obtaining romidepsin. With the method, eventually prepared romidepsin has purity of greater than 99% and overall yield of greater than 30%; and the method has the advantages of simple operation, a short synthesis period, low cost and capacity of realizing large-scale production of romidepsin.
82. 103893125 阿尼芬净纳米粒及其制备方法
CN
02.07.2014
A61K 9/14 Loading...
A61K 9/14
Loading...
201210571693.0
深圳翰宇药业股份有限公司
徐春莲
A61K 9/14
Loading...
本发明涉及医药技术领域，尤其涉及阿尼芬净纳米粒及制备方法。本发明提供的阿尼芬净纳米粒包括阿尼芬净、载体和表面活性剂；该阿尼芬净纳米粒的，粒径为50nm~500nm。其制备方法为：分别配制油相和内水相；将油相与内水相混合并进行第一超声乳化，得到初乳；配制外水相；将初乳与外水相混合并进行第二超声乳化，得到复乳，干燥、洗涤，即得。本发明提供的阿尼芬净纳米粒将阿尼芬净包裹于纳米粒载体体系中，增加了稳定性、增强了溶解速率，提高了生物利用度。另外，本发明在阿尼芬净纳米粒的制备过程中引入潜溶剂，并在后续步骤中除去，解决了阿尼芬净溶解性的问题，提高了阿尼芬净纳米粒的品质。
83. 103880946 Preparation method of Carperitide
CN
25.06.2014
C07K 14/58 Loading...
C07K 14/58
Loading...
201210556840.7
深圳翰宇药业股份有限公司
张文治
C07K 14/58
Loading...
The invention discloses a method for synthesizing Carperitide by employing an Fmoc route solid-liquid combination fragment method, in the method, multiple fragments are simultaneously synthesized, the synthesis period is reduced by 2/3, an intermediate is easily purified, the cost is low, the purity of final product is high, the by-product is little, the product yield is high, and the preparation method is in favor of large-scale production of Carperitide.
84. 103884808 一种齐考诺肽及其杂质的检测方法
CN
25.06.2014
G01N 30/88 Loading...
G01N 30/88
Loading...
201210562697.2
深圳翰宇药业股份有限公司
康旭
G01N 30/88
Loading...
本发明涉及一种用于有效分离和分析齐考诺肽及其杂质的高效液相色谱（HPLC）方法。
85. 103864901 Method for preparing nepadutant and intermediate thereof and intermediate
CN
18.06.2014
C07K 9/00 Loading...
C07K 9/00
Loading...
201210547948.X
深圳翰宇药业股份有限公司
宓鹏程
C07K 9/00
Loading...
The invention relates to a method for preparing nepadutant and an intermediate thereof and the intermediate. The method comprises taking resin P as a carrier, according to Fmoc solid-phase synthetic method, sequentially coupling six substances shown in the specification for obtaining a peptide resin; performing intra-cyclization, deprotection, cyclization and cracking to obtain a deprotected bicyclic peptide, namely the nepadutant intermediate; and reacting the intermediate with acetyl glucosamine under the condition of a liquid phase, so as to obtain nepadutant.
86. 203648103 旋转蒸发器
CN
18.06.2014
B01D 1/00 Loading...
B01D 1/00
Loading...
201320891133.3
深圳翰宇药业股份有限公司
康旭
B01D 1/00
Loading...
本实用新型涉及实验室教学及工业生产中的一种仪器，尤其涉及一种旋转蒸发器，其包括加热装置、置于所述加热装置中的蒸发瓶、连接所述蒸发瓶并倾斜设置的冷凝装置以及设于所述冷凝装置下侧的回收瓶，其中，所述旋转蒸发器还包括由压力传感器和中央控制器组成的气泡控制装置，当有气泡产生时，中央控制器在接收到所述压力传感器发送的压力信号，及时调整旋转器的转速，继而避免在旋转蒸发过程中产生气泡。本实用新型由于设有气泡控制装置，能在旋蒸过程中起泡情况下自动降低转速，从而避免气泡的产生，蒸馏液喷溅，产生不必要的浪费，也避免了因蒸馏液喷溅而影响实验和生产结果；同时在运行过程中无须操作人员监控，可有效节约人力成本。
87. 103848893 Purifying method of linaclotide
CN
11.06.2014
C07K 7/08 Loading...
C07K 7/08
Loading...
201210523956.0
深圳翰宇药业股份有限公司
覃亮政
C07K 7/08
Loading...
The invention belongs to the technical field of pharmaceutical chemistry and discloses a purifying method of linaclotide. The purifying method comprises the following steps: by taking porous graphitized carbon as an immobile phase and taking a mobile phase with certain concentration of gamma-cyclodextrin as a three-dimensional selective agent, separating and purifying coarse linaclotide by high performance liquid chromatography; then, removing gamma-cyclodextrin and phosphate out of a purified linaclotide eluant by high performance liquid chromatography and converting into acetate; and freezing to obtain the fine linaclotide. The purifying method provided by the invention is simple to operate, so that the operating cost is low. In addition, the purifying method is high in yield of linaclotide, so that the method is suitable for large-scaled industrial production of linaclotide, and the purity of the purified fine linaclotide is over 99%. The linaclotide is high in purity and low in content of impurities. Therefore, the purifying method has considerable economical and practical values as well as wide application prospect.
88. 103833842 一种辛卡利特的制备方法
CN
04.06.2014
C07K 14/595 Loading...
C07K 14/595
Loading...
201410105423.X
深圳翰宇药业股份有限公司
唐青林
C07K 14/595
Loading...
本发明涉及多肽药物合成技术领域，尤其涉及一种辛卡利特的制备方法。该方法包括：固相合成Fmoc-Phe-树脂；按照辛卡利特肽序，在Fmoc-Phe-树脂上依次偶联氨基酸，制得辛卡利特肽树脂；辛卡利特肽树脂经裂解、沉淀，制得辛卡利特粗品；辛卡利特粗品经溶解、纯化、转盐、冻干，即得。本发明的偶联剂可提高偶联效果，降低因-Tyr（SO3Na）偶联困难而产生的副产物含量。裂解采用盐浴的方式，可防止磺酰基团的脱落，因此，本发明提供的方法可以在保证辛卡利特产品的纯度不降低的前提下，提高产品的稳定性。以本发明提供方法制备的辛卡利特收率可达42%，纯度>99%；配制成水溶液放置48h后，杂质含量未见明显增多。
89. WO/2014/067084 METHOD FOR PREPARING EXENATIDE
WO
08.05.2014
C07K 14/575 Loading...
C07K 14/575
Loading...
PCT/CN2012/083795
HYBIO PHARMACEUTICAL CO., LTD.
MI, Pengcheng
C07K 14/575
Loading...
Disclosed in the present invention is a method for preparing Exenatide. Serine resin is obtained through a first coupling of serine and resin and successively with amino acids through a second coupling to obtain a peptide resin with a sequence as shown by SEQ ID No. 1; Exenatide resin is obtained through a third coupling of histidine containing a protecting group or salts thereof and the peptide resin with a sequence as shown by SEQ ID No. 1, then it is cracked and purified to obtain purified Exenatide peptide. The method for preparing Exenatide of the present invention inhibits the formation of D-His-Exenatide, and thereby improves the yield and purity of Exenatide.
90. 103705910 一种齐考诺肽注射型皮下植入剂及其制备方法
CN
09.04.2014
A61K 38/17 Loading...
A61K 38/17
Loading...
201310751946.7
深圳翰宇药业股份有限公司
郑春莲
A61K 38/17
Loading...
本发明属于药物制备技术领域，公开了一种齐考诺肽注射型皮下植入剂的制备方法以及采用该方法制备得到的齐考诺肽注射型皮下植入剂。通过本发明的方法制备得到的植入剂，在使用前，用灭菌注射用水溶解后，再注入人体皮下组织即可。通过本发明的方法制备得到的植入剂是一种缓控释制剂新剂型，可以以液体形式注射到皮下，在体温的作用下，溶液变成凝胶，在体内缓慢释放，实现治疗止痛的长效效果。
91. WO/2014/047822 METHOD FOR PREPARATION OF BUSERELIN
WO
03.04.2014
C07K 7/23 Loading...
C07K 7/23
Loading...
PCT/CN2012/082119
HYBIO PHARMACEUTICAL CO., LTD.
ZHANG, Wenzhi
C07K 7/23
Loading...
Provided in the present invention is a method for preparing buserelin by the solid phase synthesis of buserelin resin and the separation of peptide chains and the resin under alkaline conditions.
92. 103694320 Preparation method of plecanatide
CN
02.04.2014
C07K 7/64 Loading...
C07K 7/64
Loading...
201310680490.X
深圳翰宇药业股份有限公司
朱日成
C07K 7/64
Loading...
The invention relates to the preparation field of polypeptide drugs and particularly relates to a preparation method of plecanatide. The method comprises the following steps: carrying out solid-phase synthesis to obtain Fmoc-Leu-resin; coupling -Cys15, -Gly, -Thr, -Cys12, -Ala, -Val, -Asn, -Val, -Cys7, -Leu, -Glu, -Cys4, -Glu, -Asp and -Asn on Fmoc-Leu-resin in sequence according to a peptide sequence of the plecanatide to prepare plecanatide linear pepetide resin, and cracking to prepare plecanatide linear crude pepetide; taking the plecanatide linear crude pepetide and carrying out first cyclizing and second cyclizing to obtain the plecanatide. The method disclosed by the invention adopts tBu or Acm as a side chain protecting group of cysteine and prepares a product which is very high in purity and yield, and accurate in disulfide bond positioning by two-step cyclizing; moreover, reaction conditions are gentle, and the preparation method is beneficial to industrial production.
93. 103675138 Ultra-high performance liquid chromatogram detection method for terlipressin and impurities thereof
CN
26.03.2014
G01N 30/02 Loading...
G01N 30/02
Loading...
201310673625.X
深圳翰宇药业股份有限公司
康旭
G01N 30/02
Loading...
The invention provides an ultra-high performance liquid chromatogram detection method for segregation analysis of terlipressin and impurities thereof. The method comprises the step of and carrying out gradient elution on the terlipressin and the impurities thereof by taking a mobile phase A and a mobile phase B which are prepared from a buffer solution and an organic solvent in different proportions as moving phases in an ultra-high performance liquid chromatograph, thereby realizing rapid segregation analysis of the terlipressin and the impurities thereof.
94. 103655570 Sitagliptin and melbine compound sustained-release preparation and preparation method thereof
CN
26.03.2014
A61K 31/4985 Loading...
A61K 31/4985
Loading...
201310675929.X
深圳翰宇药业股份有限公司
左灵静
A61K 31/4985
Loading...
The invention relates to the technical field of medicines, and in particular relates to a sitagliptin and melbine compound sustained-release preparation and a preparation method thereof. The compound sustained-release preparation comprises a sustained-release part, a quick-release part and a blank auxiliary, wherein the sustained-release part comprises metformin hydrochloride, pellets, a binder, a sustained-release coating layer and a plasticizer; the quick-release part comprises sitagliptin or a pharmaceutically acceptable salt thereof, a filler and a binder; the blank auxiliary comprises a disintegrating agent, a lubricant and a gastric-soluble coating layer. In the compound sustained-release preparation, a plurality of unit sustained-release pellets are prepared from metformin hydrochloride in the sustained release part, each pellet can release drugs independently and is stable in drug release speed, and the plurality of pellets are widely distributed in the gastrointestinal tract to release drugs, so that over-high concentration of the drugs at local parts can be effectively avoided, and the irritation of metformin hydrochloride to the stomach can be reduced. The problem of metformin hydrochloride dosage pouring of each sustained-release tablet caused by broken coating film or dose fractionation can be solved, so that the possibility of adverse response occurrence can be reduced.
95. 103665147 Synthetic method of growth hormone releasing factor derivative
CN
26.03.2014
C07K 14/60 Loading...
C07K 14/60
Loading...
201310613886.2
SHENZHEN HYBIO PHARMACEUTICAL CO., LTD.
CHEN YONGHAN
C07K 14/60
Loading...
A synthetic method of a growth hormone releasing factor derivative relates to a solid-phase synthetic method of CJC-1295. According to the method, amino resin is taken as a carrier, starting from Fmoc-Lys(Tfa)-resin, amino acid is coupled one by one, and trifluoroacetyl protecting groups are desorbed by cheaper reagents. The method is more suitable for large-scale industrial operations, and a brand-new thought is provided for the large-scale production of the CJC-1295.
96. 103641897 Method of synthesizing glatiramer acetate
CN
19.03.2014
C07K 14/00 Loading...
C07K 14/00
Loading...
201310617060.3
深圳翰宇药业股份有限公司
李国弢
C07K 14/00
Loading...
The invention belongs to the technical field of drug synthesis and discloses a method of synthesizing glatiramer acetate. The method comprises the following steps of adding an acid-binding agent which does not participate in polymerization reaction to consume a hydrogen chloride gas adsorbed by amino acid NCA (No Carrier Added); and then, adding a diethylamine initiator. Average molecular weight of fully-protected glatiramer obtained by the method can be conveniently controlled within a certain range, so that quality of the glatiramer acetate is controlled more stably, and qualification rate of products is improved.
97. 103641894 Preparation method of polypeptide medicine for treating cushing disease
CN
19.03.2014
C07K 7/64 Loading...
C07K 7/64
Loading...
201310656466.2
深圳翰宇药业股份有限公司
宓鹏程
C07K 7/64
Loading...
The invention belongs to the technical field of medical chemistry, discloses a preparation method of a polypeptide medicine for treating the cushing disease, and in particular relates to a preparation method of pasireotide. The preparation method uses Fmoc-Lys-OAll as a raw material, and comprises the following steps: coupling by adopting a pure solid phase synthesizing method to obtain Fmoc-Pro(4-OH)-Phg-D-Trp(Boc)-Lys(C TC)-OAll; coupling with Boc-NH-C2H4-NH-COOH on the premise that the Fmoc protecting group is not removed to synthesize side chain amino acid; coupling the amino acid protected by Fmoc in sequence, removing the protecting group-All at C terminal, cyclizing to obtain pasireotide resin, and performing cracking purification to obtain pasireotide. Compared with the prior art, the preparation method is easily available in raw materials, few in reaction steps and high in pasireotide yield, and is suitable for large-scale production of pasireotide; the prepared pasireotide is high in purity.
98. 103641891 Method for preparing Kahalalide F
CN
19.03.2014
C07K 7/08 Loading...
C07K 7/08
Loading...
201310196587.3
深圳翰宇药业股份有限公司
陈新亮
C07K 7/08
Loading...
The invention relates to a preparation method for Kahalalide F. The method comprises steps: 2-CTC resin is employed as a carrier, polypeptide segments A and B are synthesized through a solid phase polypeptide synthesis method; the polypeptide segment B is subjected to a molecule esterification reaction and a segment Bi is synthesized; the the polypeptide segments A and Bi are subjected to liquid phase condensation; protecting groups are removed and Kahalalide F is obtained. The method has high yield and convenient post-treatment, and provides a new ideal for industrial scale production of Kahalalide F.
99. 103626849 Method for preparing linaclotide
CN
12.03.2014
C07K 7/08 Loading...
C07K 7/08
Loading...
201310617050.X
深圳翰宇药业股份有限公司
戴政清
C07K 7/08
Loading...
The invention belongs to the technical field of medicine synthesis, and discloses a method for synthesizing linaclotide by three pairs of total selectively formed disulfide bonds. By using the process, formation of three pairs of disulfide bonds in linaclotide can be sequentially completed in the same solution system, so that the operation method of the process is simple, the yield of final fine peptide of linaclotide can be greatly increased, and large-scale production can be realized.
100. 103622913 Tetracosactide lipidosome and preparation method thereof
CN
12.03.2014
A61K 9/127 Loading...
A61K 9/127
Loading...
201310661286.3
深圳翰宇药业股份有限公司
颜携国
A61K 9/127
Loading...
The invention belongs to the technical field of drug synthesis and discloses a tetracosactide lipidosome capable of being administrated through the nose in a spraying manner. The tetracosactide lipidosome has the characteristics of rapid absorption and effect taking, high bioavailability, accurate therapeutic effect and convenience for use. The liver first-pass effect of the drug is effectively avoided, and meanwhile, the non-compliance of injection administration is avoided. Besides, the invention further discloses a method for preparing the tetracosactide lipidosome. According to the method, the tetracosactide lipidosome is prepared by a thin-film evaporation and high-pressure homogenization process.
101. 103626848 一种环酯肽Orfamide A的固相合成方法
CN
12.03.2014
C07K 7/06 Loading...
C07K 7/06
Loading...
201310631343.3
深圳翰宇药业股份有限公司
宓鹏程
C07K 7/06
Loading...
本发明属于药物合成技术领域，公开了一种纯固相合成环酯肽Orfamide？A的方法。该方法能够高效，规模化地生产环酯肽Orfamide？A。
102. WO/2014/032257 METHOD FOR PREPARING BIVALIRUDIN
WO
06.03.2014
C07K 1/04 Loading...
C07K 1/04
Loading...
PCT/CN2012/080792
HYBIO PHARMACEUTICAL CO., LTD.
MI, Pengcheng
C07K 1/04
Loading...
Provided is a method for preparing bivalirudin. The method comprises preparing polypeptide fragments, and coupling the polypeptide fragments, amino acid and solid state carrier into bivalirudin peptide resin, and then cracking and purifying it to obtain bivalirudin. The method utilizes the characteristic that there are hydrophobic and charged amino acid residues at both sides of Gly-Gly-Gly-Gly in the bivalirudin to prepare the polypeptide fragments as the raw material, and effectively separating impurities by the differences of polarity and charge to avoid the occurrence of impurity in the bivalirudin in which 1 or 2 Gly are lost or added.
103. 103585114 一种改进的制备艾塞那肽缓释微球的方法
CN
19.02.2014
A61K 9/16 Loading...
A61K 9/16
Loading...
201310608433.0
深圳翰宇药业股份有限公司
刘慧
A61K 9/16
Loading...
本发明属于药物制剂领域，公开了一种改进的制备艾塞那肽缓释微球的方法以及由该方法制备的艾塞那肽缓释微球。在本发明的方法中，先将聚合物在二氯甲烷中溶解后，再与甲醇溶液混合，保证聚合物较快溶解后，再加入艾塞那肽或艾塞那肽和保护剂，加快了艾塞那肽和聚合物的溶解速率，减少了艾塞那肽与有机溶剂的接触时间以及聚合物溶解过程中溶剂的挥发损失，同时极大地提高了艾塞那肽在油相中的溶解度，提高了载药量，减少了药物在制备过程中的降解，简化了工艺，缩短了制备周期。
104. 103554224 Telaprevir preparation method
CN
05.02.2014
C07K 7/06 Loading...
C07K 7/06
Loading...
201310370210.5
深圳翰宇药业股份有限公司
陈友金
C07K 7/06
Loading...
The invention belongs to the pharmaceutical chemistry field, and especially relates to a telaprevir preparation method. The preparation method comprises the following steps: reacting an initial raw material 2-pyrazinecarboxylic acid with L-cyclohexylglycine by adopting a smallest protection strategy, reacting with L-tert-leucine, reacting with (1S,3aR,6aS)-octahydro-cyclopenta[c]pyrrole-1-carboxylic acid to obtain a compound 7, wherein the synthesis step is shortened; and condensing the compound 7, a compound 8 and cyclopropane to obtain telaprevir. The preparation method has the advantages of avoiding of the adoption of a low-yield oxidation reaction in the synthesis, synthesis yield improvement, cheap and easily available raw materials, mild reaction conditions, and suitableness for the large scale production.
105. 103517915 Method for preparing Buserelin
CN
15.01.2014
C07K 7/23 Loading...
C07K 7/23
Loading...
201280010255.5
深圳翰宇药业股份有限公司
张文治
C07K 7/23
Loading...
The invention provides a method for preparing Buserelin through solid-phase synthesis of Buserelin resin and separation of peptide chains from the resin in alkaline conditions.
106. 103494769 Compound in-situ gel long-acting injection for treating chronic hepatitis and preparation method thereof
CN
08.01.2014
A61K 9/06 Loading...
A61K 9/06
Loading...
201310467495.4
深圳翰宇药业股份有限公司
颜携国
A61K 9/06
Loading...
The invention relates to the technical field of medicine, and discloses a compound in-situ gel long-acting injection for treating chronic hepatitis and a preparation method thereof. The compound in-situ gel long-acting injection for treating chronic hepatitis, disclosed by the invention, is prepared from 5-24 parts of zinc salt interferon a or magnesium salt interferon a, 150-800 parts of thymalfasin, 1800-12000 parts of in-situ gel materials, and 8000-100000 parts of solvent. The compound in-situ gel long-acting injection disclosed by the invention is prepared from the thymalfasin, the interferons and proper in-situ gel materials. Thus, the administration frequency is reduced; the medicine effect can be stably and lastingly released for a long period of time; the compound in-situ gel long-acting injection is free of obvious toxic and side effects, and high in medicine concentration and encapsulation efficiency; the product quality is superior to the specified standard; the compound in-situ gel long-acting injection is suitable for popularization and application in treatment of the chronic hepatitis.
107. 103432570 Thymalfasin sustained-release microspheres and preparation method thereof
CN
11.12.2013
A61K 38/22 Loading...
A61K 38/22
Loading...
201310409424.9
深圳翰宇药业股份有限公司
刘慧
A61K 38/22
Loading...
The invention relates to the technical field of medicines and discloses thymalfasin sustained-release microspheres and a preparation method thereof. The method comprises the following steps: freeze-drying and sieving an aqueous solution of thymalfasin; collecting the thymalfasin powder; grinding and sieving polylactic acid or a polylactide-co-glycolide acid (PLGA); mixing the obtained polymer powder and the thymalfasin powder to obtain a mixture of raw and accessory materials; melting and extruding the mixture of raw and accessory materials to obtain a hot-melting extrudate; cooling to cure the hot-melting extrudate; cutting, grinding and sieving to obtain the thymalfasin sustained-release microspheres. According to the invention, the thymalfasin sustained-release microspheres are prepared by a hot-melting extrusion technology without needing an organic solvent, the problem of residual organic solvent is completely avoided, a few impurities are contained, and the drug release is steady; an advantage of continuously releasing the thymalfasin dose is realized, thus the administration time is reduced, the administration pain of a patient is eased, and the thymalfasin sustained-release microspheres are suitable to be popularized and applied to treatment.
108. 103408637 Preparation method of eptifibatide
CN
27.11.2013
C07K 7/06 Loading...
C07K 7/06
Loading...
201310263341.3
深圳翰宇药业股份有限公司
康旭
C07K 7/06
Loading...
The invention relates to the field of preparation of polypeptides and particularly relates to a preparation method of eptifibatide. The preparation method comprises the following steps of: preparing a fine peptide solution of the eptifibatide; and performing rotary evaporation on the fine peptide solution of the eptifibatide to get a fine peptide concentrated solution of the eptifibatide, and freeze-drying to obtain eptifibatide, wherein the concentration of the fine peptide concentrated solution of the eptifibatide is 15-30mg/mL; and the temperature of rotary evaporation is 25 DEG C-35 DEG C. The preparation method of the fine peptide solution of the eptifibatide comprises the following steps of: coupling Cys with resin to get Cys-resin; and gradually coupling the Cys-resin with Pro, Trp, Asp, Gly, Har and Mpr to get a peptide with the sequence as shown in SEQ (sequence) ID (identity) NO: 1, and further performing oxidation, cracking, purification and salt transfer to get the fine peptide solution of the eptifibatide. By adopting the preparation method provided by the invention, the production of dimer impurities in the eptifibatide can be greatly reduced, and organic residues of acetonitrile and the like can be in line with the related standard in Chinese Pharmacopoeia.
109. 103396475 Pure-solid-phase synthesis method of polypeptide antibiotic Colistin
CN
20.11.2013
C07K 7/62 Loading...
C07K 7/62
Loading...
201310339190.5
深圳翰宇药业股份有限公司
宓鹏程
C07K 7/62
Loading...
The invention belongs to the technical field of medicine synthesis, and discloses a method of pure-solid-phase synthesis of polypeptide antibiotic Colistin. By use of the method, the synthetic process and procedure of the Colistin are simplified, the synthesis time is shortened, and the use amount of solvents is reduced.
110. 103335873 测量氨基酸‑N‑甲酸酐中氯离子含量的方法
CN
02.10.2013
G01N 1/28 Loading...
G01N 1/28
Loading...
201310219049.1
深圳翰宇药业股份有限公司
李国弢
G01N 1/28
Loading...
本发明涉及制备可用于测量N‑羧基酸酐中氯离子含量的溶液，以及测量N‑羧基酸酐中氯离子含量的方法。本发明还涉及制备具有高纯度N‑羧基酸酐的方法，以及制备得到的具有高纯度N‑羧基酸酐。此外，本发明还涉及制备具有高纯度多肽混合物的方法，以及由此制备得到的多肽混合物，尤其地，多肽混合物是醋酸格拉替雷。
111. 103319570 一种比伐卢定的制备方法
CN
25.09.2013
C07K 7/08 Loading...
C07K 7/08
Loading...
201310210329.6
深圳翰宇药业股份有限公司
宓鹏程
C07K 7/08
Loading...
本发明公开了一种通过顺序偶联制备比伐卢定的方法，其中Gly的投料比显著高于其他相应氨基酸的投料比，具体地，Gly的投料比为4-8倍。
112. 103304641 一种纯化WALP肽的方法
CN
18.09.2013
C07K 14/00 Loading...
C07K 14/00
Loading...
201310203789.6
深圳翰宇药业股份有限公司
唐青林
C07K 14/00
Loading...
本发明提供了一种纯化WALP肽的方法，包括以下步骤：1）采用反相色谱法对粗肽溶液进行纯化，其中以非极性键合硅胶或弱极性键合硅胶为固定相，甲醇为流动相A，乙腈为流动相B，进行梯度洗脱，收集目的峰值的肽溶液，所述流动相A和流动相B相都含有三氟乙酸或甲酸；2）将所收集的肽溶液旋蒸冻干。通过本方法纯化得到的多肽纯度高，收率高，并且本方法操作简单，成本低。
113. 103304639 一种纯化去氨加压素中间体的方法
CN
18.09.2013
C07K 7/16 Loading...
C07K 7/16
Loading...
201310227482.X
深圳翰宇药业股份有限公司
唐青林
C07K 7/16
Loading...
本发明提供了一种使用反相高压液相色谱纯化去氨加压素中间体的方法，该方法使用甲酸水溶液和乙腈作为流动相，使得线性去氨加压素中间体的纯化在反相制备柱上操作更容易，出峰更窄，不拖尾，收率更高，收率达到95％以上。
114. 103304624 一种多肽的制备方法
CN
18.09.2013
C07K 1/10 Loading...
C07K 1/10
Loading...
201310242802.9
深圳翰宇药业股份有限公司
潘俊锋
C07K 1/10
Loading...
本发明涉及多肽合成领域，特别涉及一种多肽的制备方法。该方法包括如下步骤：获得第一多肽片段-第一树脂、第二多肽片段-第二树脂、第三多肽片段、第四多肽片段、氨基端乙酰化的第五多肽片段；脱除第二多肽片段-第二树脂中Glu和Lys的侧链保护基，经环化、第一裂解，获得第二多肽片段；依次将第二多肽片段、第三多肽片段、第四多肽片段、氨基端乙酰化的第五多肽片段与第一多肽片段-第一树脂偶联，获得肽树脂，经第二裂解、纯化、冻干，即得。本发明提供的制备方法合成周期短，合成杂质少，易纯化，可提高最终产品的收率。
115. 103304659 利拉鲁肽的固相制备方法
CN
18.09.2013
C07K 14/605 Loading...
C07K 14/605
Loading...
201310243206.2
深圳翰宇药业股份有限公司
潘俊锋
C07K 14/605
Loading...
本发明涉及多肽合成领域，特别涉及利拉鲁肽的固相制备方法。本发明将困难序列或包含困难序列的单个片断连接到树脂上，其他区域仍采用逐步偶联的方法进行氨基酸连接,粗肽纯度和收率都显著提高，且成本相对较低。
116. 103304661 一种肽醛的制备方法
CN
18.09.2013
C07K 14/81 Loading...
C07K 14/81
Loading...
201310222464.2
深圳翰宇药业股份有限公司
张文治
C07K 14/81
Loading...
本发明属于药物合成技术领域，公开了一种肽醛的制备方法，其依次包括制备保护的氨基醛、制备氨基醛连接臂、制备肽醛-树脂复合物和切割纯化得到肽醛纯品的步骤，其中在制备氨基醛连接臂时所采用的连接臂为二丙醇胺或二丁醇胺。本发明所采用的二丙醇胺和二丁醇胺作为连接臂制备肽醛的方法对20种常用氨基酸均适用，适用范围更广，并且有效克服了紧邻消旋杂峰的存在。因此，本发明提供了一种简便、高效的制备肽醛方法，解决了目前肽醛制备工艺繁琐、周期长、产率低、易消旋等问题。
117. 103301058 一种特立帕肽注射用组合物及其制备方法和制剂
CN
18.09.2013
A61K 9/08 Loading...
A61K 9/08
Loading...
201310239123.6
深圳翰宇药业股份有限公司
徐春莲
A61K 9/08
Loading...
本发明涉及医药技术领域，尤其涉及一种特立帕肽注射用组合物及其制备方法和制剂。该特立帕肽注射用组合物，包括特立帕肽、冻干保护剂和pH调节剂；其中，特立帕肽与冻干保护剂的质量比为1：（10～100000）。该特立帕肽注射用组合物配方简单，冻干保护剂保证特立帕肽在制备及保藏过程中不会发生降解，pH调节剂在制备过程中调节pH值且可调节特立帕肽注射用组合物复溶后的pH值，进一步维持特立帕肽的稳定性。且所用辅料安全，不会引起毒性反应。因此，本发明提供的特立帕肽注射用组合物稳定性好、配方组成简单合理，且复溶性能好，可制备成为粉针剂或注射液而无需制备成为笔式注射器，生产工艺简单。
118. 103288951 一种利拉鲁肽的制备方法
CN
11.09.2013
C07K 14/605 Loading...
C07K 14/605
Loading...
201310243204.3
深圳翰宇药业股份有限公司
潘俊锋
C07K 14/605
Loading...
本发明涉及多肽合成领域，特别涉及一种利拉鲁肽的制备方法。该制备方法包括如下步骤：取Gly与树脂偶联，得到Gly-树脂；取Gly-树脂经第一逐步偶联，得到多肽片段-树脂；取多肽片段-树脂经侧链修饰、第二逐步偶联、裂解、纯化、冻干，即得；多肽片段-树脂中多肽片段的序列如SEQ ID NO：1所示；利拉鲁肽的序列如SEQ ID NO：2所示；侧链修饰具体为：脱除多肽片段-树脂中Lys侧链的保护基，依次偶联Fmoc-Glu-OtBu、棕榈酰氯。利用该制备方法制得的利拉鲁肽中，杂质少，易纯化，可提高最终产品的收率。
119. 103288923 醋酸胸腺五肽规模化制备方法
CN
11.09.2013
C07K 7/06 Loading...
C07K 7/06
Loading...
201310243202.4
深圳翰宇药业股份有限公司
赵忠卫
C07K 7/06
Loading...
本发明涉及多肽制备领域，特别涉及胸腺五肽规模化制备方法。采用如下步骤：获得Tyr-树脂；以氨基酸为第一原料，取Tyr-树脂经第一逐步偶联进行第一批次固相合成，获得第一肽片段-树脂，分别收集逐步偶联的反应液备用；以反应液为第二原料，取Tyr-树脂经第二逐步偶联进行第二批次固相合成，获得第二肽片段-树脂；补充氨基酸作为第三原料，取Tyr-树脂经第三逐步偶联进行第三批次固相合成，获得第三肽片段-树脂；合并第一肽片段-树脂、第二肽片段-树脂和第三肽片段-树脂，裂解，纯化即得。该方法的氨基酸利用率达到67.8%以上，显著提高了氨基酸利用率。
120. 103293255 一种艾塞那肽及其杂质超高效液相色谱检测方法
CN
11.09.2013
G01N 30/36 Loading...
G01N 30/36
Loading...
201310101282.X
深圳翰宇药业股份有限公司
康旭
G01N 30/36
Loading...
本发明涉及一种用于分离分析艾塞那肽及各杂质的超高效液相色谱方法。具体而言，本发明的方法包括选用柱色谱法，以缓冲液与有机溶剂不同比例配制的流动相A和流动相B为流动相，梯度洗脱艾赛那肽及各杂质，从而实现对艾赛那肽与其中间体及杂质的快速分离和分析测定。
121. 103275189 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用
CN
04.09.2013
C07K 7/08 Loading...
C07K 7/08
Loading...
201310222465.7
深圳翰宇药业股份有限公司
张文治
C07K 7/08
Loading...
本发明属于药物合成技术领域，公开了一种用于肽树脂的裂解液，其由以下体积百分比的组分组成：三氟乙酸（TFA）85%～90%，1,2-乙二硫醇（EDT）0%～10%，水0%～10%，苯甲醚（PhOMe）0%～10%，其中组分EDT、水和PhOMe中至少两个不同时为0。此外，本发明还公开了一种制备生长抑素的方法以及上述裂解液在制备生长抑素中的应用，其中采用上述裂解液进行裂解反应。经过分析比对试验，采用本发明改进的裂解液对固相合成树脂进行裂解，有效提高了粗肽纯度和氧化肽的转化率，氧化反应收率提高接近10%。因此，本发明具有明显的经济效益，可以有效降低生产成本。
122. 103272220 一种醋酸盐布舍瑞林脂质微泡及其制备方法
CN
04.09.2013
A61K 38/09 Loading...
A61K 38/09
Loading...
201310222462.3
深圳翰宇药业股份有限公司
颜携国
A61K 38/09
Loading...
本发明属于药物合成技术领域，公开了一种醋酸盐布舍瑞林脂质微泡（BLM）及其制备方法。该脂质微泡包括类脂质双分子层膜，连接于所述类脂质双分子层外侧的醋酸盐布舍瑞林和包裹在所述类脂质双分子层内部的惰性气体。通过本发明的方法所制备的醋酸盐布舍瑞林微泡作为药物载体，具有良好的靶向性，从而减少了药物剂量，降低了毒性，减少了副作用，并且结构简单、制备方便。此外，其可以与超声技术联合应用，实现了药物在靶部位定点的、可视化的释放。同时其在靶点部位自身超声爆破时产生超声空化效应，极大地提高了药物在组织中的通透性，实现了量效的最大化。
123. 103275207 一种制备奈西立肽的方法
CN
04.09.2013
C07K 14/58 Loading...
C07K 14/58
Loading...
201310094866.9
深圳翰宇药业股份有限公司
肖庆
C07K 14/58
Loading...
本发明涉及一种制备奈西立肽的方法，其操作简单、成本低、制备周期短和/或总收率高（＞25%），有利于大规模生产。所述制备奈西立肽的方法包括：制备5个片段，将所述片段依次偶联得到线型奈西立肽，然后经氧化得到奈西立肽，所述方法任选地包括纯化奈西立肽的步骤。
124. WO/2013/117135 METHOD FOR PURIFYING SOLID-PHASE SYNTHETIC CRUDE LIRAGLUTIDE
WO
15.08.2013
C07K 14/605 Loading...
C07K 14/605
Loading...
PCT/CN2013/071063
HYBIO PHARMACEUTICAL CO., LTD.
QIN, Liangzheng
C07K 14/605
Loading...
The present invention relates to the field of biomedicine, and in particular, to a method for purifying solid-phase synthetic crude liraglutide. The method comprises: dissolving solid-phase synthetic crude liraglutide in an aqueous acetonitrile solution to obtain a crude peptide solution; and obtaining liraglutide with high purity and high yield through four-step HPLC purification.
125. WO/2013/117122 METHOD FOR PURIFYING ATOSIBAN
WO
15.08.2013
C07K 1/20 Loading...
C07K 1/20
Loading...
PCT/CN2013/070505
HYBIO PHARMACEUTICAL CO., LTD.
ZHAO, Zhongwei
C07K 1/20
Loading...
The present invention belongs to the technical field of pharmaceutical chemistry.Disclosed is a method for purifying atosiban. The purification method of the present invention comprises: treating the solution of the crude peptide of atosiban with a ferric ion salt as a reducing agent, removing the impurities that are not completely oxidized in the solution, subsequently purifying the solution of the crude peptide of atosiban with high-performance liquid chromatography, and then preparing the purified product of the atosiban by converting same to a salt from the resulting purified atosiban perchlorate using reversed-phase high-performance liquid chromatography. The purification method of the present invention is operationally simple and feasible, and the prepared purified peptide of the atosiban has a high level of purity; meanwhile, the purified peptide of the atosiban produced through the method of the present invention has a high yield, with greater than 1000 g of purified peptide of atosiban being able to be obtained in a batch, which is sufficient to meet industrial requirements.
126. 103214568 一种固相制备促胰液素的方法
CN
24.07.2013
C07K 14/645 Loading...
C07K 14/645
Loading...
201310073954.0
深圳翰宇药业股份有限公司
姚志军
C07K 14/645
Loading...
本发明提供了一种固相制备促胰液素的方法，包括以下步骤：1)选择合适的固相载体；2)按照固相合成方法，逐个偶联氨基酸；3)裂解，得到粗肽；4)粗肽经纯化得到促胰液素，其中固相合成采用Fmoc-策略，并在固相合成中以假脯氨酸代替肽链中的部分丝氨酸。本发明提供了一种操作简单、杂质少、易纯化、收率高、有利于实现产业化的固相制备促胰液素的方法。
127. 103204821 一种制备氨基酸N-羧基环内酸酐的方法
CN
17.07.2013
C07D 263/44 Loading...
C07D 263/44
Loading...
201310075935.1
深圳翰宇药业股份有限公司
李国弢
C07D 263/44
Loading...
本发明提供一种制备氨基酸N-羧基环内酸酐的方法。所述方法包括以无水四氢呋喃作为溶剂，在一种三光气分解催化剂的存在下，将氨基酸与三光气进行反应生成相应的氨基酸N-羧基环内酸酐。在所述方法中，通过引入三光气分解催化剂，有助于提高加快三光气的分解速率，不仅缩短了反应时间，而且可显著地提高氨基酸-NCA的收率。特别是当氨基酸中的R基团较短时，反应收率大大提高。
128. 103204923 固相片段法制备卡培立肽
CN
17.07.2013
C07K 14/58 Loading...
C07K 14/58
Loading...
201310093066.5
深圳翰宇药业股份有限公司
张文治
C07K 14/58
Loading...
本发明公开了一种采用Fmoc路线固液结合片段法合成卡培立肽的方法，该方法中多个片段合成同时进行，合成周期减少了2/3，中间体易纯化，成本低，最终产品纯度高，副产物少，产品收率高，利于卡培立肽的大规模生产，使用本发明的方法得到的粗肽纯度为75%以上，总收率达到25%以上。
129. 103204922 一种制备奈西立肽的方法
CN
17.07.2013
C07K 14/575 Loading...
C07K 14/575
Loading...
201310096382.8
深圳翰宇药业股份有限公司
肖庆
C07K 14/575
Loading...
本发明提供了一种制备奈西立肽的方法，其通过低替代度的氨基酸树脂、小片段和不同侧链保护基来减少缺省肽的产生，提高粗肽纯度，有利于纯化，提高收率。
130. 103183727 一种卷曲霉素的制备方法
CN
03.07.2013
C07K 7/56 Loading...
C07K 7/56
Loading...
201210547992.0
深圳翰宇药业股份有限公司
陈友金
C07K 7/56
Loading...
本发明涉及一种卷曲霉素的制备方法，具体而言，涉及一种固相合成卷曲霉素的方法，包括：使Fmoc-Ser(tBu)-OH或Fmoc-Ala-OH在有机碱的存在下于溶剂中与树脂反应，生成Fmoc-Ser(tBu)-树脂或Fmoc-Ala-树脂，经脱保护和偶联步骤得到线性全保护树脂，然后经裂解、成环、脱保护得到所需产物。
131. 103169670 Acetic acid copaxone microsphere and preparation method thereof
CN
26.06.2013
A61K 9/16 Loading...
A61K 9/16
Loading...
201310096288.2
深圳翰宇药业股份有限公司
王博
A61K 9/16
Loading...
The invention relates to an acetic acid copaxone microsphere and a preparation method thereof. The preparation method is simple in process, and the encapsulation efficiency of the prepared acetic acid copaxone microsphere is high and stable in quality.
132. 103156806 Thymalfasin in-situ gel preparation and preparation method thereof
CN
19.06.2013
A61K 9/06 Loading...
A61K 9/06
Loading...
201310102435.2
深圳翰宇药业股份有限公司
颜携国
A61K 9/06
Loading...
The invention relates to the field of pharmaceutic preparations, and in particular relates to a thymalfasin in-situ gel preparation and a preparation method thereof. The thymalfasin in-situ gel preparation is composed of thymalfasin, an in-situ gel material and an organic solvent, wherein the mass-volume ratio of the thymalfasin, the in-situ gel material and the organic solvent based on g/g/mL is (2-4.5):(15-35):(100-150). The thymalfasin in-situ gel preparation provided by the invention has sustained release function, can be used for preventing the peak valley phenomenon of blood concentration, reducing the admission time as the medicament action time is long, greatly easing the pain of patients and improving the compliance of the patients and has no irritation for the skin and connective tissues. The method for preparing the thymalfasin in-situ gel preparation is simple, high in medicament loading capacity and low in cost, and is conductive to large-scale production.
133. 103145809 Method for preparing anidulafungin
CN
12.06.2013
C07K 7/56 Loading...
C07K 7/56
Loading...
201210557066.1
深圳翰宇药业股份有限公司
韦畅勇
C07K 7/56
Loading...
The invention relates to a solid phase-liquid phase full synthetic method for preparing anidulafungin. The method comprises that Fmoc-P-resin serves as a carrier, a solid phase polypeptide synthetic method is adopted to gradually couple amino acid with an Fmoc protecting group from the C end to the N end, and then the protecting group is deprived through splitting, intramolecular reaction and liquid phase condensation to obtain the anidulafungin. The method is high in yield, brings convenience to aftertreatment and provides a new thinking way for industrial scale production of the anidulafungin.
134. 103145810 一种制备米卡芬净的方法
CN
12.06.2013
C07K 7/56 Loading...
C07K 7/56
Loading...
201210558336.0
深圳翰宇药业股份有限公司
姚志军
C07K 7/56
Loading...
本发明涉及制备米卡芬净的固相-液相全合成方法，所述方法包括以Fmoc-P-CTC树脂为载体，采用固相多肽合成方法从C端到N端逐一偶联上带有Fmoc保护基的氨基酸，再通过裂解、分子内反应、液相缩合，脱除保护基得到米卡芬净。本发明的方法收率高且后处理方便，为米卡芬净的工业规模生产提供了一种新的思路。
135. WO/2013/078889 THE METHOD FOR PREPARING EXENATIDE BY NATURAL COUPLING
WO
06.06.2013
C07K 14/575 Loading...
C07K 14/575
Loading...
PCT/CN2012/080760
HYBIO PHARMACEUTICAL CO., LTD.
MI, Pengcheng
C07K 14/575
Loading...
Disclosed is a method for preparing exenatide, comprising the following steps: 1) dividing exenatide into several peptide segments, which are obtained through a solid phase synthetic method, comprising peptide segments, N-terminal of which is Thr or Ser, and other peptide segments required for forming exenatide; 2) forming an acid ester structure at the C-terminal of peptide segment coupled with the N-terminal of the peptide segment in step 1), N-terminal of which is Thr or Ser; removing the side chain protection group of the peptide segment; 3) removing the side chain protection group and N-terminal protection group of the peptide segment, N-terminal of which is Thr or Ser; 4) using the peptide segments said in step 2) and step 3) to couple in the liquid phase to obtain exenatide with N-terminal being protected; 5) removing the N-terminal amino protection group and purifying to obtain exenatide. The method is easy to operate, and able to control intermediates, carried out in a short reaction period and cost-effective for preparing exenatide with high yield.
136. 103122023 一种曲普瑞林的纯化方法
CN
29.05.2013
C07K 7/23 Loading...
C07K 7/23
Loading...
201310074154.0
深圳翰宇药业股份有限公司
付信
C07K 7/23
Loading...
本发明提供了一种曲普瑞林的纯化方法，首先用含有机溶剂的水溶液溶解样品，以十八烷基硅烷键合硅胶为固定相，以磷酸或硫酸的缓冲盐为A相，乙腈为B相，进行梯度洗脱；然后，采用反相HPLC方法，以十八烷基硅烷键合硅胶为固定相，将曲普瑞林磷酸盐转成醋酸盐、冻干得到纯度大于99.7%单杂小于0.05%的醋酸曲普瑞林，总收率高达30%以上。本发明提供了一种成本低廉、高收率、工艺过程简单、样品杂质少且稳定可控、有利于实现产业化的曲普瑞林纯化工艺。
137. 103102395 一种醋酸去氨加压素的制备方法
CN
15.05.2013
C07K 7/16 Loading...
C07K 7/16
Loading...
201210551550.3
深圳翰宇药业股份有限公司
唐青林
C07K 7/16
Loading...
本发明属于药物化学技术领域，公开了一种醋酸去氨加压素的制备方法。本发明所述醋酸去氨加压素的制备方法采用固相合成法合成线性去氨加压素肽树脂，裂解得到线性去氨加压素粗肽，然后通过反相高效液相色谱法纯化线性去氨加压素粗肽后再进行液相氧化，最后转盐得到醋酸去氨加压素。与现有技术相比，本发明所述制备方法结合固相合成和液相氧化的优点，将固相合成、纯化和液相氧化相结合，操作简单、生产成本低、环境污染小、醋酸去氨加压素收率高，适合于醋酸去氨加压素大规模产业化生产，并且制得的醋酸去氨加压素产品质量好，纯度高、杂质含量低，具有可观的经济实用价值和广泛的应用前景。
138. 103073619 一种酯肽的制备方法
CN
01.05.2013
C07K 7/06 Loading...
C07K 7/06
Loading...
201210369972.9
深圳翰宇药业股份有限公司
陈友金
C07K 7/06
Loading...
本发明涉及化学合成肽领域，具体涉及一种酯肽的制备方法。该方法通过逐步偶联、将Asp的羧基与Ser的氨基通过偶联剂发生脱水缩合反应连接成环、去除Thr的保护基后将3-（2-戊基）-苯丙酸与Thr的氨基端发生脱水缩合反应后，经裂解、沉淀、纯化后获得结构如式Ⅰ所示的酯肽。该方法具有定向合成的特点，对相关杂质的分析较发酵方法有更强的可溯性和可控性，且在合成阶段可将相关杂质降低到一定的限度，在提高产品纯度的基础上，降低了纯化的难度和提高了产品的收率。本发明工艺的监测只需要通过简单的Kaiser检测，操作简单，对设备要求不高。式Ⅰ
139. 103027898 一种西他列汀缓释微丸及其制备方法
CN
10.04.2013
A61K 9/16 Loading...
A61K 9/16
Loading...
201210586436.4
深圳翰宇药业股份有限公司
左灵静
A61K 9/16
Loading...
本发明涉及缓释药物制剂领域，特别涉及一种西他列汀缓释微丸及其制备方法。该西他列汀缓释微丸由载药素丸和缓释衣层组成，载药素丸与缓释衣层的质量比为1︰0.08～0.12，载药素丸由药物有效成分、丸芯和粘合剂组成，药物有效成分、丸芯、粘合剂的质量比为40～80︰15～55︰1～10；药物有效成分为西他列汀或其药学上可接受的盐；缓释衣层由缓释材料、增塑剂和致孔剂组成，缓释材料、增塑剂、致孔剂的质量比为60～80︰5～15︰10～30。本发明提供的西他列汀缓释微丸具有明显的缓释作用，避免了药物浓度的峰谷现象，降低了药物对人体的毒副作用，提高了药物的生物利用度，减少了给药次数，且提高了患者的顺应性。
140. WO/2013/044714 NEW METHOD FOR PREPARING D-ISOGLUTAMYL-D-TRYPTOPHAN
WO
04.04.2013
C07D 209/20 Loading...
C07D 209/20
Loading...
PCT/CN2012/080754
HYBIO PHARMACEUTICAL CO., LTD.
ZENG, Guoliang
C07D 209/20
Loading...
A preparation method of D-isoglutamyl-D-tryptophan (D-iGlu-D-Trp-OH) comprises the following steps: (A) activating R1-D-Glu-OR2 under an HONb condition, to obtain R1-D-Glu(ONb)-OR2 (II); condensing with D-Trp-OR2 in an alkaline condition, to obtain R1-D-Glu(D-Trp-OR2)-OR2 (IV), and purifying the product through crystallization; and (C) removing protection groups R1 and R2 through hydrogenation, to obtain D-iGlu-D-Trp-OH (V).
141. 102993293 一种特立帕肽醋酸盐的纯化方法
CN
27.03.2013
C07K 14/635 Loading...
C07K 14/635
Loading...
201210514757.3
深圳翰宇药业股份有限公司
赵忠卫
C07K 14/635
Loading...
本发明提供了一种特立帕肽醋酸盐的纯化方法，包括以下步骤：以体积比10%—30%的醋酸和5%—20%的乙腈水溶液溶解粗肽；将粗肽溶液进行梯度洗脱纯化，以体积比0.1%—0.4%的硫酸和体积比0.1%—0.4%醋酸的水溶液用氨水调pH值5.0—6.0后的溶液为A相，乙腈为B相，梯度：B%：20%—40%洗脱；盐析；用含3%—10%乙腈的醋酸铵溶液冲洗，用十八烷基硅烷键合硅胶高效液相色谱进行转盐，醋酸水溶液乙腈体系洗脱。本发明的目的是提供一种操作简单、高收率、纯度高、有利于实现产业化的特立帕肽的纯化方法。
142. 102993274 一种醋酸加尼瑞克的纯化方法
CN
27.03.2013
C07K 7/23 Loading...
C07K 7/23
Loading...
201210504961.7
深圳翰宇药业股份有限公司
戴柱
C07K 7/23
Loading...
本发明提供了一种醋酸加尼瑞克的纯化方法，包括以下步骤：(1)加尼瑞克粗肽的纯化：采用以十八烷基硅烷键合硅胶为固定相，以一定浓度高氯酸盐/磷酸溶液为A相，以乙腈为B相，梯度洗脱的HPLC方法纯化加尼瑞克粗肽；(2)转盐及纯化：然后采用以烷基硅烷键合硅胶为固定相，以一定浓度冰醋酸溶液为A相，以乙腈为B相，梯度洗脱的HPLC方法转盐纯化，收集溶液冻干即得到醋酸加尼瑞克。本发明的目的是提供一种工艺稳定可控、高收率、纯度高、具有广泛的实用价值和应用前景的加尼瑞克的纯化方法。
143. WO/2013/037266 METHOD FOR SOLID PHASE SYNTHESIS OF LIRAGLUTIDE
WO
21.03.2013
C07K 1/04 Loading...
C07K 1/04
Loading...
PCT/CN2012/080756
HYBIO PHARMACEUTICAL CO., LTD.
PAN, Junfeng
C07K 1/04
Loading...
Provided is a method for solid phase synthesis of liraglutide, comprising the following steps: A) Fmoc-Gly-resin being obtained by coupling resin solid phase carrier with glycine with N-end protected by Fmoc(Fmoc-Gly-OH) in the presence of activator system; B) according to the peptide sequence of the main chain of liraglutide, successively coupling with amino acids with N-ends protected by Fmoc and protected side chains by the method for solid phase synthesis, wherein lysine employs FmOC-LyS(Alloc)-OH; C) removing the protecting group, Alloc, from the side chain of lysine; D) coupling the side chain of lysine with Palmitoyl-Glu-Offiu by the method for solid phase synthesis; E) cleavage, removing protection groups and resin to obtain crude liraglutide; F) purifying and lyophilizing to obtain liraglutide.
144. WO/2013/037267 VARIANT OF LIRAGLUTIDE AND CONJUGATE THEREOF
WO
21.03.2013
C07K 14/605 Loading...
C07K 14/605
Loading...
PCT/CN2012/080758
HYBIO PHARMACEUTICAL CO., LTD.
PAN, Junfeng
C07K 14/605
Loading...
Provided in the present invention is a variant of liraglutide and a preparation method thereof, wherein the amino acid sequence of the variant of liraglutide is X1-Ala-Glu-X2-Thr-Phe-X3-X4-Asp-Val-X5-X6-Tyr-Leu-X7-Gly-Gln-Ala-X8-Lys(N-ε-(N-α-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-X9-Trp-X10-Val-Arg-Gly-Arg-X11; wherein X1 is His or Cys; X2 is Gly or Cys; X3 is Thr or Cys; X4 is Ser or Cys; X5 is Ser or Cys; X6 is Ser or Cys; X7 is Glu or Cys; X8 is Ala or deleted; X9 is Ala or Cys; X10 is Leu or Cys or D-Ala; X11 is Gly or Cys or Gly-Gly. Also provided in the present invention is a conjugate of the variant of liraglutide and a preparation method thereof. The variant of liraglutide and conjugate thereof provided in the invention retain biological activity of liraglutide, prolong the half-life, and are advantageous for relieving the patient's burden.
145. 102924575 一种比伐卢定的制备方法
CN
13.02.2013
C07K 7/08 Loading...
C07K 7/08
Loading...
201210428012.5
深圳翰宇药业股份有限公司
朱日成
C07K 7/08
Loading...
本发明涉及多肽合成领域，特别涉及一种比伐卢定的制备方法。该方法采用固相合成的多肽片段Fmoc-D-Phe-Pro-Arg(Pbf)-Pro-Gly-Gly-Gly-OH为原料，避免了Bivalirudin±1Gly和Bivalirudin±2Gly的问题；此外，本发明采用特定偶联试剂使该异构体L-Phe的量大大降低；同时提高了产品的收率和纯度，操作简便，条件温和，有利于实现规模化的制备。
146. 102702325 Preparation method of anticoagulant polypeptide
CN
03.10.2012
C07K 7/08 Loading...
C07K 7/08
Loading...
201210203147.1
深圳翰宇药业股份有限公司
宓鹏程
C07K 7/08
Loading...
The invention relates to a preparation method of an anticoagulant polypeptide and discloses a preparation method of bivalirudin, and belongs to the technical field of pharmaceutical chemistry. The preparation method comprises the following steps: purifying a bivalirudin crude peptide by a reverse phase/weak cation exchange mixed-mode HPLC (high performance liquid chromatography) method; transferring a salt by a reverse phase HPLC method; and collecting and lyophilizing a solution to obtain the bivalirudin. The preparation method is easy to operate, low in cost and high in gram yield of the bivalirudin and is applicable for large-scale industrial production of the bivalirudin; by virtue of hydrophobicity and chargeability difference, impurities in the crude peptide can be separated and removed well at one time; and the prepared bivalirudin is high in purity and low in impurity content and has a considerable economic value and a wide application prospect.
147. WO/2012/083861 METHOD FOR PREPARING ATOSIBAN ACETATE
WO
28.06.2012
C07K 7/06 Loading...
C07K 7/06
Loading...
PCT/CN2011/084414
HYBIO PHARMACEUTICAL CO., LTD
XIAO, Qing
C07K 7/06
Loading...
Provided is a method for preparing atosiban acetate, comprising the following steps: synthesizing linear atosiban; dissolving linear atosiban in an aqueous acetonitrile solution, adjusting the pH value with aqueous ammonia, oxidizing with H2O2, filtering, purifying, and converting into a salt, to obtain atosiban acetate. The present invention provides a suitable route to synthesize linear atosiban through a solid-phase method and obtain atosiban through liquid-phase oxidation. The method solves the problem that linear atosiban is difficult to dissolve, reduces the reaction volume and shortens the reaction time as far as possible. The method has a high yield, and can be easily industrialized.
148. 102429876 利拉鲁肽缓释微球制剂及其制备方法
CN
02.05.2012
A61K 9/16 Loading...
A61K 9/16
Loading...
201110417193.7
深圳翰宇药业股份有限公司
颜携国
A61K 9/16
Loading...
一种利拉鲁肽缓释微球制剂的配方，主要由5-60份利拉鲁肽，50-200份生物可降解基质材料组成，生物可降解基质材料是：聚乳酸、聚乳酸-羟基乙酸嵌段共聚物，乙交酯-丙交酯共聚物，聚乙醇酸、聚己内酯、聚乳酸-羟基乙酸-聚己内酯共聚物或PLCG-聚己内酯，或其中任意两种或两种以上的混合物。优选聚乳酸-羟基乙酸-聚己内酯共聚物。本发明的缓释微球包封率高、缓释效果好。
149. 102423484 一种稳定的西曲瑞克药物组合物及其制备方法
CN
25.04.2012
A61K 38/08 Loading...
A61K 38/08
Loading...
201110376326.0
深圳翰宇药业股份有限公司
郑春莲
A61K 38/08
Loading...
本发明涉及一种稳定的西曲瑞克药物组合物及其制备方法，采用以下方法制备获得：(1)制备甘露醇、醋酸西曲瑞克溶液，过滤；(2)将步骤（1）的溶液分装至容器，分步降温；第一阶段，以降温速率不大于3℃/min，将板层温度降至-25℃--40℃，并保温，保温时间不低于1小时；第二阶段，继续降温至-40℃或以下，保温时间不低于1小时；(3)干燥得冻干药物组合物。通过该方法制备获得药物组合物具有稳定性好，经过长时间保存依然具有确切疗效的优势。
150. 102417474 D-异谷氨酰基-D-色氨酸制备的新方法
CN
18.04.2012
C07D 209/20 Loading...
C07D 209/20
Loading...
201110288091.X
深圳翰宇药业股份有限公司
曾国良
C07D 209/20
Loading...
本发明提供一种D-异谷氨酰基-D-色氨酸（D-iGlu-D-Trp-OH）制备方法，包含以下步骤：(A)R1-D-Glu-OR2在HONb条件下活化，得到R1-D-Glu(ONb)-OR2(II)；(B)在碱性条件下与D-Trp-OR2缩合，得到R1-D-Glu（D-Trp-OR2）-OR2（IV），结晶纯化；(C)通过氢化脱除保护基R1和R2，得到D-iGlu-D-Trp-OH（V）；该方法通过控制中间体R1-D-iGlu-D-Trp-OR2的纯度可有效控制产品中的杂质，纯化工艺简单，可得到高纯度D-iGlu-D-Trp-OH，缩短了合成路线，大幅度提高收率，利于节约生产成本。
151. 102382188 醋酸卡培立肽的制备方法
CN
21.03.2012
C07K 14/58 Loading...
C07K 14/58
Loading...
201110347965.4
深圳翰宇药业股份有限公司
张文治
C07K 14/58
Loading...
本发明公开了一种醋酸卡培立肽的制备方法，包括以下步骤：1）由Fmoc-Tyr(tBu)-OH和替代度为0.5mmol/g-1.0mmol/g的WangResin反应，得到Fmoc-Tyr(tBu)-WangResin；2）将Fmoc-Tyr(tBu)-WangResin树脂采用逐一偶联的方式合成得到线性卡培立肽-WangResin；3）采用固相氧化法氧化卡培立肽-WangResin；4）采用TFA裂解，得到粗肽；5）对卡培立肽粗肽进行反相高效液相色谱法纯化，得到高纯度精肽。该工艺具有反应操作简单、后处理容易、收率高、成本低等有益的技术效果。
152. 102329373 地加瑞克的固相合成工艺
CN
25.01.2012
C07K 7/06 Loading...
C07K 7/06
Loading...
201110292168.0
深圳翰宇药业股份有限公司
陈友金
C07K 7/06
Loading...
本发明涉及地加瑞克的一种固相合成方法，包括以下步骤：1）树脂与Fmoc-D-Ala-OH得到Fmoc-D-Ala-树脂；树脂是氨基树脂；2）采用Fmoc固相合成策略依次将按地加瑞克的氨基酸排列顺序进行连接；3）去除N端Fmoc，用乙酸酐和吡啶进行乙酰化；4）去除C端第6个氨基酸残基-4Aph（X）上的保护基X；5）将L-4,5-dihydrooroticacid连接到C端第6个氨基酸残基-4Aph的侧链氨基上；6）用裂解试剂切割肽树脂，无水乙醚沉淀，离心后得粗肽；7）经纯化分离得地加瑞克。本发明操作简单，对人体和环境危害小，且该工艺有效的降低了杂质的含量，能够进行规模化生产。
153. 102321170 利拉鲁肽变构体及其缀合物
CN
18.01.2012
C07K 14/605 Loading...
C07K 14/605
Loading...
201110271343.8
深圳翰宇药业股份有限公司
潘俊锋
C07K 14/605
Loading...
本发明提供一种利拉鲁肽变构体及其制备方法，利拉鲁肽变构体的氨基酸序列为：X1-Ala-Glu-X2-Thr-Phe-X3-X4-Asp-Val-X5-X6-Tyr-Leu-X7-Gly-Gln-Ala-X8-Lys(N-ε-(N-α-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-X9-Trp-X10-Val-Arg-Gly-Arg-X11；其中：X1为His或Cys；X2为Gly或Cys；X3为Thr或Cys；X4为Ser或Cys；X5为Ser或Cys；X6为Ser或Cys；X7为Glu或Cys；X8为Ala或删除；X9为Ala或Cys；X10为Leu或Cys或D-Ala；X11为Gly或Cys或Gly-Gly。本发明还提供一种利拉鲁肽变构体缀合物及其制备方法。本发明提供的利拉鲁肽变构体及其缀合物保留了利拉鲁肽的生物学活性，延长了半衰期，有利于患者负担的减轻。
154. 102319418 一种布舍瑞林制剂及其制备方法
CN
18.01.2012
A61K 38/09 Loading...
A61K 38/09
Loading...
201110248693.2
深圳翰宇药业股份有限公司
郑春莲
A61K 38/09
Loading...
本发明提供一种稳定的布舍瑞林药物制剂及其制备方法。药物制剂包含布舍瑞林和缓冲剂,制剂的pH为4.0--6.5，所述的缓冲剂为枸橼酸盐缓冲液，醋酸盐缓冲液，酒石酸盐缓冲液、磷酸盐缓冲液或磷酸氢二钠-枸橼酸缓冲液中的任意一种或其任意两种或两种以上的组合。本发明的制剂稳定性明显提高。
155. 102286092 Solid-phase synthesis method of liraglutide
CN
21.12.2011
C07K 14/605 Loading...
C07K 14/605
Loading...
201110271342.3
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Pan Junfeng
C07K 14/605
Loading...
The invention provides a solid-phase synthesis method of liraglutide, comprising the following steps: (A) coupling a resin solid-phase carrier and glycine (Fmoc-Gly-OH) with N-end Fmoc protection in the existence of an activating agent system to obtain Fmoc-Gly-resin; (B) sequentially coupling amino acids with N-end Fmoc protection and side chain protection according to a liraglutide main chain peptide sequence by using the solid-phase synthesis method, wherein lysine adopts Fmoc-Lys(Alloc)-OH; (C) removing a protective group Alloc of a side chain of the lysine; (D) coupling Palmitoyl-Glu-OtBu to the side chain of the lysine by using the solid-phase synthesis method; (E) splitting and removing the protective group and the resin to obtain crude peptide of the liraglutide; and (F) purifying and freeze-drying to obtain the liraglutide. The solid-phase synthesis method provided by the invention has the advantages of simplicity in operation, short synthesis period, low production cost, reduction of waste liquid, easiness in aftertreatment, less byproducts and high yield of products and is beneficial for large-scale production of the liraglutide.
156. 102228678 Carbetocin pharmaceutical composition and preparation method thereof
CN
02.11.2011
A61K 38/11 Loading...
A61K 38/11
Loading...
201110169532.4
Shenzhen Hybio Pharmaceutical Co.,Ltd.
Zheng Chunlian
A61K 38/11
Loading...
The invention relates to a stable pharmaceutical composition containing carbetocin, and a preparation method thereof. The stable pharmaceutical composition containing carbetocin contains carbetocin, a pH regulator, an isoosmotic regulator and pharmaceutically acceptable auxiliary materials. The composition is used for preventing uterine atony and postpartum hemorrhage after selective epidural or spinal anesthesia cesarean section. The pharmaceutical composition mainly exists in a liquid form and is used through parenteral administration forms, mainly injection and nasal spray.
157. 102210872 Polyethylene glycol modified peptide pharmaceutical formulation and preparation method thereof
CN
12.10.2011
A61K 47/48 Loading...
A61K 47/48
Loading...
201110142527.4
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Tao Anjin
A61K 47/48
Loading...
The invention discloses a polyethylene glycol modified peptide pharmaceutical formulation and a preparation method thereof. The pharmaceutical formulation comprises polyethylene glycol modified peptide and a buffering agent, wherein the pH of the formulation is 4.0-7.0, the buffering agent is one or any two or a combination of more than two of an acetate buffering solution, a citrate buffering solution, a phosphate buffering solution and a tartrate buffering solution. The preparation method comprises the following steps of: weighing the buffering agent of a formulated amount, dissolving with injection water and transferring into a solution-preparing tank; dissolving the polyethylene glycol modified peptide of the formulated amount with the solution, and diluting until a formulated concentration is reached; carrying out filtration sterilization with a filtering film to obtain a polyethylene glycol modified injection solution. The long-term stability of the formulation disclosed by the invention is remarkably improved.
158. 102198103 Stable exenatide sustained-release microsphere preparation and preparation method thereof
CN
28.09.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
201110142532.5
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Tao Anjin
A61K 9/16
Loading...
The invention provides a stable exenatide sustained-release microsphere preparation and a preparation method thereof. The preparation contains 0.1 to 12.5 mass percent of exenatide and 77.5 to 99 percent of glycolide and lactide copolymer. The preparation method comprises the following steps: (a) dissolves glycolide and lactide copolymer in an organic solvent to form an oil phase, wherein the organic solvent may be one or the combination of dichloromethane and ethyl acetate; (b) dissolving exenatide, a protective agent and a suspending aid in water to form an internal water phase; (c) mixing the internal water phase and the oil phase to form emulsion; and (d) after the organic solvent violates, obtaining exenatide-containing sustained-release microspheres. As the formula composition of the stable exenatide sustained-release microsphere preparation is reasonable, the stable exenatide sustained-release microsphere preparation is prepared by common sustained-release microsphere technique, and the sustained-release period of the sustained-release microspheres is as long as 7 to 35 days. The technical effect is better when the exenatide sustained-release microspheres are prepared by a multiple emulsion (water-oil-water) method.
159. 102127146 Method for preparing atosiban acetate
CN
20.07.2011
C07K 7/06 Loading...
C07K 7/06
Loading...
201010604790.6
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Xiao Qing
C07K 7/06
Loading...
The invention provides a method for preparing atosiban acetate. The method comprises the following steps of: synthesizing to obtain linear atosiban; dissolving the linear atosiban in an acetonitrile aqueous solution; adjusting the pH value with ammonia water; adding H2O2 for oxidizing; filtering; purifying; and transferring salt to obtain the atosiban acetate. In the invention, an appropriate route is provided, the linear atosiban is synthesized by adopting a solid phase method, and the atosiban is obtained by liquid phase oxidation. The method has the advantages of capabilities of solving the problem of insolubility of the linear atosiban, reducing the reaction size to the maximum extent and shortening reaction time, and being high in yield and easy to industrialize.
160. 102106828 Thymalfasin sustained-release microsphere preparation and preparation method thereof
CN
29.06.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
201110046147.0
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Tao Anjin
A61K 9/16
Loading...
The invention provides a thymalfasin sustained-release microsphere preparation and a preparation method thereof. The thymalfasin sustained-release microsphere preparation comprises the following components in percentage by weight: 0.1 to 10 percent of thymalfasin, and 85 to 99 percent of poly(glycolide-co-lactide), wherein the poly(glycolide-co-lactide) is copolymer of glycolide and lactide, the ratio of the glycolide to the lactide is (25:75)-(75:25), the molecular weight of the poly(glycolide-co-lactide) is between 5,000 and 35,000 dalton, and the intrinsic viscosity is between 0.1 and 0.5dL/g. The pH value of the external water phase of the thymalfasin sustained-release microsphere preparation is between 3.0 and 5.0, and can be regulated by adopting acetic acid, hydrochloric acid, sulfuric acid and the like. The inventor discovers that by controlling the pH value of the external water phase, the stability of the thymalfasin can be improved and the entrapment rate in a preparation process also can be improved, so that the drug-loading rate of sustained-release microspheres can be improved.
161. 102100906 Medicinal preparation of exenatide and preparation method thereof
CN
22.06.2011
A61K 38/22 Loading...
A61K 38/22
Loading...
201110040615.3
Shenzhen Hybio Pharmaceutical Co., Ltd.
Tao Anjin
A61K 38/22
Loading...
The invention provides a medicinal preparation of exenatide and a preparation method thereof. The preparation comprises a protective agent, a buffering agent, an isotonic regulator, 0.001 to 1.0 percent of preservative and 0.005 to 0.5 percent (w/v) of exenatide, and the pH value of the preparation is between 3.0 and 7.0, wherein the protective agent is one or a combination of two or more of polysorbate 80, lecithin, pluronic F68 and human serum albumin. The preparation method comprises the following steps of: (1) weighing prescription dose of preservative, isotonic regulator and buffering agent, dissolving sequentially by using water for injection and putting the mixture into a liquid preparation tank; (2) dissolving the exenatide in the solution, and diluting to the prescription concentration; and (3) filtering and sterilizing by using a filter membrane of 0.22 micrometer to obtain exenatide injection. The long-term stability of the preparation is improved obviously, and the preparation contains 0.005 to 0.5 percent (w/v) of exenatide, the protective agent, the buffering agent, the isotonic regulator and the preservative.
162. 102068685 Terlipressin preparation and preparations method thereof
CN
25.05.2011
A61K 38/11 Loading...
A61K 38/11
Loading...
201010147970.6
Shenzhen Hybio Pharmaceutical Co.,Ltd.
Xie Shengkun
A61K 38/11
Loading...
The invention discloses a terlipressin preparation and a preparations method thereof, belonging to the field of medical preparations. The terlipressin preparation comprises active components and auxiliary materials; the active components include terlipressin and pharmaceutically acceptable salts; the auxiliary materials include excipient and a pH regulator; and the weight part ratio of the terlipressin to the excipient to the pH regulator is (1-50):(1-1000):(1-200). Because the terlipressin is easy to degrade under the condition of acid or base, found by research of the invention, the stability of the active components in the terlipressin preparation can be greatly enhanced by selecting a proper pH range. With the pH range determined in the proportion range of the active components to the excipient to the pH regulator determined by the invention, researched by stability test, the stability of the active components is greatly enhanced, and the drug effect period of the active components is greatly prolonged under the same storage condition.
163. 102002004 Taltirelin intermediate and synchronizing method of taltirelin
CN
06.04.2011
C07D 239/22 Loading...
C07D 239/22
Loading...
201010509468.5
Shenzhen Hybio Pharmaceutical Co., Ltd.
Chen Youjin
C07D 239/22
Loading...
The invention discloses a taltirelin intermediate and a synchronizing method of taltirelin. The taltirelin intermediate is 3-methyl hydroorotic acid and L-histidine-L-proline amide. The invention discloses a synchronizing method of the 3-methyl hydroorotic acid, which mainly comprises the steps of: reacting L-Asn with ethyl chloroformate, and then obtaining hydroorotic acid under the action of sodium ethoxide; reacting with benzyl bromide; reacting with methyl iodide under the action of NaH to obtain 3-methyl benzyl hydroorotic; and hydrogenating to obtain 3-methyl hydroorotic acid. The invention also discloses a synchronizing method of the L-histidine-L-proline amide and a synchronizing method of taltirelin. The invention provides a more appropriate path, the taltirelin is synchronized by using a liquid phase process, the reaction raw materials are easy to obtain, the reaction condition is mild and the operation is simple.
164. 101935339 Solid-phase preparation method for buserelin
CN
05.01.2011
C07K 7/23 Loading...
C07K 7/23
Loading...
201010256054.6
Shenzhen Hybio Pharmaceuticals Co., Ltd.
Chen Dalai
C07K 7/23
Loading...
The invention provides a solid-phase preparation method for buserelin. The method comprises the following steps of: 1) preparing a Fmoc-Pro-HMPB-MBHA resin with degree of substitution of between 0.15 and 0.80mmol/g from Fmoc-Pro-OH and a HMPB-MBHA resin with degree of substitution of between 0.2 and 0.9mmol/g by a solid-phase synthesis method; 2) gradually coupling remaining protected amino acid of the Fmoc-Pro-HMPB-MBHA resin according to a peptide sequence to obtain buserelin-HMPB-MBHA resin; 3) cracking the buserelin-HMPB-MBHA resin to obtain fully-protected peptide; and 4) performing ethyl amination, deprotection and purification on the obtained fully-protected peptide to obtain buserelin. The invention aims to provide a buserelin solid-phase synthesis method which has the advantages of high yield, low cost, mild reaction conditions, small environmental pollution and contribution to realizing industrialization.
165. 101798334 Purification method of human parathyroid hormone (1-34)
CN
11.08.2010
C07K 1/20 Loading...
C07K 1/20
Loading...
201010138985.6
Hybio Pharmaceutical Co., Ltd.
Dai Zhu
C07K 1/20
Loading...
The invention provides a purification method of human parathyroid hormone (1-34), which is suitable for industrialization and comprises the following steps: 1) taking octadecylsilane chemically bonded silica as a stationary phase, taking 0.05-0.2% trifluoroacetic acid aqueous solution as A phase and acetonitrile as B phase with the gradient of 20-40% of B%, and carrying out gradient elution to rough peptide solution; and 2) adopting the opposite-phase high performance liquid chromatography to convert the trifluoroacetic acid salt of human parathyroid hormone (1-34) into acetate. The purification method of human parathyroid hormone (1-34), which is provided by the invention, has simple and feasible operation, high purity and high yield, and produced human parathyroid hormone (1-34) can reach the industrialization requirement.
166. 101798335 Purification method of thymosin extrasin alpha 1
CN
11.08.2010
C07K 1/20 Loading...
C07K 1/20
Loading...
201010138995.X
Hybio Pharmaceutical Co., Ltd.
Dai Zhu
C07K 1/20
Loading...
The invention provides a technical method applicable to the industrialized purification of thymosin extrasin alpha 1, which comprises the following steps: using octadecylsilane chemically bonded silica as a fixed phase; using a trifluoroacetic acid water solution as a phase A, using acetonitrile as a phase B; controlling the gradient (B%) between 10 and 60 percent; carrying out gradient elution on a crude peptide solution; and carrying out the step of salt conversion, wherein the thymosin extrasin with trifluoroacetic acid salt is converted into salt-free thymosin extrasin by a reverse-phase efficient liquid phase chromatography method. The invention adopts the one-step reverse-phase efficient liquid phase chromatography method for purification, and uses the reverse-phase efficient liquid phase chromatography method for converting the salt, so the purified thymosin extrasin alpha 1 has high purification and high yield, and the industrialization requirement can be met.
167. 101787071 Purification method of vapreotide
CN
28.07.2010
C07K 1/20 Loading...
C07K 1/20
Loading...
201010116374.1
Hybio Pharmaceutical Co., Ltd.
Ma Yaping
C07K 1/20
Loading...
The invention provides a purification method of vapreotide, which comprises the following steps: 1) taking octadecylsilane chemically bonded silica as fixed phase, taking acetate buffer solution with the pH value of 3.0-4.5 as A phase, taking acetonitrile as B phase and carrying out gradient elution on crude peptide solution at the gradient: B%: 20-40%; and 2) adopting the reversed-phase high performance liquid chromatography for converting the crude peptide solution to acetate. The method has the advantages of high purity and good yield and achieves the requirements on industrialization, thereby providing an effective purification process for mass purification and prepration of vapreotide pharmaceutical raw materials.
168. 101780267 Platelet aggregation inhibition preparation and preparation method thereof
CN
21.07.2010
A61K 38/08 Loading...
A61K 38/08
Loading...
201010124592.X
Shenzhen Hybio Pharmaceutical Co., Ltd.
Li Hongling
A61K 38/08
Loading...
The invention discloses a platelet aggregation inhibition preparation, which belongs to the technical field of biomedicine. The platelet aggregation inhibition preparation comprises active ingredients and an auxiliary material, wherein the concentration of the active ingredients is 0.1-50 mg/ml, and the active ingredients are eptifibatide and pharmaceutically-acceptable eptifibatide derivatives; the auxiliary material is a buffer system of citric acid and sodium citrate; and in the buffer system, the concentrations of the citric acid and the sodium citrate are respectively 0.5-50 mg/ml and 0.5-50 mg/ml. The six-month accelerated test and the 24-month long-term stability test prove that the active ingredients are stable in the injection prepared from the eptifibatide preparation. In particular, the small volume injection prepared from the eptifibatide preparation has the advantages of good stability and accurate curative effect, and can maintain good stability during storage and transportation.
169. 101781367 Method for purifying human parathyroid hormone (1 to 34)
CN
21.07.2010
C07K 14/815 Loading...
C07K 14/815
Loading...
201010116391.5
Shenzhen Hybio Pharmaceutical Co., Ltd.
Fu Xin
C07K 14/815
Loading...
The invention relates to a method for purifying human parathyroid hormone (1 to 34). The invention provides a method suitable to industrially purify lepirudin, which comprises the following steps: (1) using octadecylsilane chemically bonded silica as a solid phase, using a phosphate buffered solution the pH value of which is between 2.5 and 3.5 as an A phase, using acetonitrile as a B phase and carrying out gradient elution on crude peptide solution, wherein the gradient B percent is between 17 and 32 percent; (2) and adopting the reversed phase high performance liquid chromatography to convert lepirudin into acetate. The method for purifying lepirudin, which is provided by the invention, has simple operation, high product purity and good yield and reaches the industrialization requirements.
170. 101747426 Method for synthesizing pramlintide
CN
23.06.2010
C07K 14/575 Loading...
C07K 14/575
Loading...
200910189086.6
Hybio Pharmaceutical Co., Ltd.
Li Hongling
C07K 14/575
Loading...
The invention discloses a method for preparing pramlintide through solid-phase synthesis. The method comprises the following steps: 1) using Fmoc-Tyr(tBu)-OH and amino resin with a substituted ratio of 0.3-1.5mmol/g to obtain Fmoc-Tyr(tBu)-amino resin; progressively coupling Fmoc-Tyr(tBu)-amino resin with residual protective amino acids according to the peptide sequence; 3) performing solid phase oxidation with iodine to ensure sulphydryl groups to form rings; 4) cracking pramlintide-resin to obtain crude pramlintide; and 5) purifying to obtain pramlintide. The technology of the invention adopts Fmoc solid phase synthesis strategy, utilizes coupling method of multiple coupling agent systems and dipeptide fragments, uses solid phase oxidation, is characterized by easy reaction operation, low cost and high yield, and is applicable to mass production.
171. 101712716 Method for preparing vapreotide
CN
26.05.2010
C07K 7/06 Loading...
C07K 7/06
Loading...
200910189087.0
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Li Hongling
C07K 7/06
Loading...
The invention discloses a method for preparing vapreotide, comprising the following steps: 1) starting from Fmoc-Trp(Boc)-OH and Rink Amide resin to obtain Fmoc-Trp(Boc)-Rink Amide resin; 2) coupling the Fmoc-Trp(Boc)-Rink Amide resin by a solid phase synthesis method to obtain linear vapreotide-Rink Amide resin according to the peptide sequence; 3) utilizing a solid phase to oxide the vapreotide-Rink Amide resin; and 4) cracking the vapreotide-Rink Amide resin, purifying and freeze-drying to obtain the vapreotide. The invention utilizes iodine to oxide the linear vapreotide resin in the solid phase, thereby avoiding the trouble brought by traditional liquid phase oxidation and improving oxidation yield by 10%-20%. The process of the invention has the characteristics of simple reaction operation, low raw material investment, low cost, high yield and the like, the total reaction yield can reach 68%, and the purification of crude peptide can reach 85%. Therefore, the method has considerable economic value and practical value.
172. 101709082 Method for preparing ziconotide
CN
19.05.2010
C07K 14/435 Loading...
C07K 14/435
Loading...
200910188686.0
ShenZhen Hybio Engineering Co., Ltd.
Li Hongling
C07K 14/435
Loading...
The invention discloses a method for preparing ziconotide. The technical scheme of the invention comprises the following steps: (1) obtaining an Fmoc-Cys(Acm)-amino resin from Fmoc-Cys(Acm)-OH and an amino resin; (2) obtaining a linear-ziconotide-amino resin of which a Cys side chain comprises Acm by performing the solid phase synthesis on the Fmoc-Cys(Acm)-amino resin and an amino acid adopting Fmoc group protection; (3) obtaining a linear crude peptide of which the Cys side chain comprises the Acm by performing cracking on the linear-ziconotide-amino resin of which the Cys side chain comprises the Acm, and obtaining linear ziconotide by removing the Acm, purifying and freeze-drying; (4) and obtaining the ziconotide by performing cyclization, purifying and freeze-drying on the linear ziconotide. The method for preparing ziconotide has the characteristics of simple reaction operation, easy subsequent treatment, low raw material investment, low cost, high yield and the like, and has considerable economic and practical value, and also has wide application prospect in the field of design synthesis of polypeptide drugs.
173. 101693738 Method for synthesizing terlipressin by solid-phase oxidization and cyclization
CN
14.04.2010
C07K 7/16 Loading...
C07K 7/16
Loading...
200910110354.0
Shenzhen Hybio Pharmaceutical Co., Ltd.
Liu Jian
C07K 7/16
Loading...
The invention discloses a method for synthesizing terlipressin by solid-phase oxidization and cyclization. The method comprises the following steps: (1) obtaining Fmoc-Gly-amino resins by using Fmoc-Gly-OH and amino resins; (2) coupling the Fmoc-Gly-amino resins one by one to obtain linear terlipressin-amino resins; (3) synthesizing the linear terlipressin-amino resins into terlipressin-amino resins by adopting iodine solid-phase oxidized cyclization; (4) cracking and cutting the terlipressin-amino resins to obtain raw peptides of the terlipressin; and (5) carrying out purification, salt conversion and freeze-drying on the raw peptides to obtain terlipressin acetate. The invention has the key innovations that solid-phase oxidization reduces a large amount of waste liquid brought by liquid-phase oxidization, accelerates the reaction time, belongs to process greening reformation and greatly improves the total yield.
174. 101602802 Process for desalting Thymosin alpha1
CN
16.12.2009
C07K 14/575 Loading...
C07K 14/575
Loading...
200910304817.7
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Chen Zhenyu
C07K 14/575
Loading...
The invention relates to a process for desalting Thymosin alpha1. The process removes salt in Thymosin alpha1 samples by an ion exchange method, and comprises the following steps: A, adjusting the pH of Thymosin alpha1 solution to be acidic; B, mixing the acidized Thymosin alpha1 solution with cation exchange resin; C, eluting ion-exchange resin with water; D, eluting exchange resin with alkaline solution and collecting eluent on the 230 nm wavelength; and E, concentrating, drying and obtaining desalted Thymosin alpha1. The process has the characteristics of large quantity of sample handling, good desalting efficiency, capability of repeated sample feeding and suitability for industrial mass production.
175. 101597325 Method for purifying Leuprorelin
CN
09.12.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200910104992.1
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Kang Xu
C07K 7/06
Loading...
The invention discloses a method for purifying Leuprorelin, which comprises the following steps: 1) after crude peptide synthesized by a solid phase is dissolved, using reverse-phase silica gel column as the solid phase, flowing-phase phosphate buffer solution as an A phase and mixed solution of chromatographic pure acetonitrile and methanol as a B phase to carry out gradient elution and purification, and collecting peptide solution of a target peak value; and 3) exchanging phosphate into acetate by adopting negative ions. The invention provides the process method which is suitable for industrialized purification of the Leuprorelin; and the method for purifying the Leuprorelin by using reverse-phase efficient liquid chromatography has high purity and good yield, and achieves the industrialized requirement.
176. 101560244 New method for synthesizing argatroban by combining solid phase method and liquid phase method
CN
21.10.2009
C07K 5/078 Loading...
C07K 5/078
Loading...
200910106759.7
Shenzhen Hybio Pharmaceutical Co., Ltd.
Liu Jian
C07K 5/078
Loading...
The invention discloses a method for synthesizing argatroban. The method comprises the following steps: the (2R, 4R)-N-Fmoc-4-methyl-2-nipecotic acid reacts with high polymer resin to obtain (2R, 4R)-N-Fmoc-4-methyl-2-nipecotic acid-resin; deprotection is carried out, Fmoc-arginyl (nitryl)-OH is coupled by a solid phase synthesis method to obtain Fmoc-arginyl (nitryl)-(2R, 4R)-4-methyl-2-nipecotic acid-resin; the deprotection is carried out again, the 3-methyl-8-quinolinesulfonyl chloride is coupled by the solid phase synthesis method to obtain 3-methyl-8-quinolinesulfonyl-arginyl (nitryl)-(2R, 4R)-4-methyl-2-nipecotic acid-resin; cracking cutting reaction is performed to the obtained resin to obtain 3-methyl-8-quinolinesulfonyl-arginyl (nitryl)-(2R, 4R)-4-methyl-2-nipecotic acid; the argatroban crude product is obtained through catalytic hydrogenation; and the argatroban is obtained through recrystallization. The method is suitable for the large-scale production and is simple and easy in operation, stable in process and low in production cost, and the total yield is up to 60 percent.
177. 101555272 Solid phase preparation method of carbetocin
CN
14.10.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200910106889.0
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Pan Junfeng
C07K 7/06
Loading...
The invention discloses a solid phase synthesis method of carbetocin. The technical proposal comprises the following steps of: obtaining Fmoc-Gly-amino resin by reaction of Fmoc-Gly-OH and amino resin with the substitutability being 0.2 mmol/g-0.9 mmol/g; sequentially connecting amino acids with Fmoc protecting groups by the solid phase synthesis method to obtain carbetocin precursor peptide I-amino resin; stripping off cysteine side chain protecting groups to obtain carbetocin precursor peptide II-amino resin; adding organic alkali and lithium chloride in solvent for cyclization to obtain carbetocin-amino resin; cracking to obtain carbetocin crude peptide; and purifying and freeze-drying to obtain the carbetocin. The method adopts the amino resin to synthesize carbetocin by the solid phase cyclization technology. The process is characterized by simple operation, easy post-treatment, high yield, low cost, and the like, and has considerable economical and practical value and broad application prospect.
178. 101538323 Method for purifying Exenatide
CN
23.09.2009
C07K 14/47 Loading...
C07K 14/47
Loading...
200910104987.0
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Kang Xu
C07K 14/47
Loading...
The invention discloses a method for purifying Exenatide, which comprises the following steps of: 1) dissolving crude peptides obtained by solid phase synthesis with water for injection; 2) conducting gradient elution and purification with the fixed phase being reversed-phase silica gel column of tetraalkylsilane bonded silica, octalkylsilane bonded silica or octadecylsilane bonded silica, and the phase A of a mobile phase being phosphate buffer solution and the phase B of the mobile phase being chromatographic grade acetonitrile, and collecting the peptide solution at a target peak value; and 3) converting the high-purity peptides after purification into acetate by using an anion exchange method. The method which is applicable to the industrialized purification of Exenatide uses reversed phase high-performance liquid chromatography for purifying Exenatide, and uses the anion exchange method for converting the high-purity peptides after purification into acetate, thus not only being capable of obtaining the refined peptides with PLC purity higher than 98.0 percent, but also realizing large-scale production and meeting the requirements of high purity, high yield and industrialization.
179. 101538324 Method for preparing Exenatide
CN
23.09.2009
C07K 14/47 Loading...
C07K 14/47
Loading...
200910104990.2
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Mi Pengcheng
C07K 14/47
Loading...
The invention discloses a method for preparing Exenatide, which comprises the following steps of: 1) using Fmoc-Ser(tBu)-OH and Sieber Amide resin with substitutability of 0.1 mmol/g to 0.8 mmol/g as starting material, and obtaining Fmoc-Ser(tBu)-Sieber Amide resin; 2) linking amino acids with protective groups in sequence by adopting a coupling way, synthesizing and obtaining Exenatide-Sieber Amide resin with full-protective lateral chains; and 3) conducting pyrolysis to the resin to remove the protective groups, precipitating with ether and obtaining crude peptides; and conducting high pressure liquid phase purification and freeze drying to the crude peptides and obtaining the Exenatide. The technology for preparing the Exenatide is characterized by simple reaction operation, easy post treatment, high yield, low cost and the like, and has considerable economical and practical value and wide application prospect.
180. 101538316 Method for preparing Eptifibatide with solid phase method
CN
23.09.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200910104994.0
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Qin Liangzheng
C07K 7/06
Loading...
The invention discloses a method for preparing Eptifibatide with a solid phase method, which comprises the following steps of: 1) selecting Sieber resin to remove Fmoc, and obtaining H2N-Sieber resin; 2) adopting Fmoc/tBu solid phase method to couple and synthesize linear peptide Eptifibatide-Sieber resin with full protective lateral chains in sequence; 3) conducting solid phase oxidation to the resin, and obtaining oxidant peptide Eptifibatide-Sieber resin with full protective lateral chains; 4) cutting the resin and removing the lateral chain protection, and obtaining crude product of Eptifibatide; and 5) conducting separation and purification, and breeze drying by a freeze dryer, and obtaining refined Eptifibatide peptide. The technology is characterized by simple operation, easy post treatment, less investment of raw material, low cost, high yield and the like, and has considerable economical and practical value and wide application prospect in the field of polypeptide drug design and synthesis simultaneously.
181. 101538315 Method for preparing Leuprorelin by combination of solid phase method and liquid phase method
CN
23.09.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200910104993.6
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Liu Jian
C07K 7/06
Loading...
The invention discloses a new technique for synthesizing Leuprorelin by the combination of a solid phase method and a liquid phase method, which comprises the following steps of: 1) using Fmoc-Pro-OH and HMPB-AM resin as starting material, and obtaining Fmoc-Pro-HMPB-AM resin; 2) coupling in sequence and synthesizing Leuprorelin precursor peptide-HMPB-AM resin with full protective lateral chains; 3) cutting the resin and obtaining Leuprorelin precursor peptide with full protective lateral chains; 4) processing the Leuprorelin precursor peptide with full protective lateral chains with methylamine, and obtaining Leuprorelin with full protective lateral chains; 5) removing the protective groups of the lateral chains of Leuprorelin with full protective lateral chains, and obtaining the crude product of Leuprorelin; and 6) conducting separation and purification and freeze drying to the crude product of Leuprorelin, and obtaining refined Leuprorelin peptide. The technology has the capability of large-scale production, easy operation, stable technique, low production cost and total yield of more than 50 percent, and has considerable economical and practical value and wide application prospect.
182. 101538314 Method for purifying Eptifibatide
CN
23.09.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200910104986.6
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Liu Jian
C07K 7/06
Loading...
The invention discloses a method for purifying Eptifibatide, which comprises the following steps of: 1) conducting suction filtration with a Buchner funnel containing diatomite to remove slightly soluble impurities; 2) conducting gradient elution and purification with the fixed phase being alkylsilane bonded silica, the phase A of a mobile phase being trifluoroacetic acid aqueous solution and the phase B thereof being chromatographic grade acetonitrile, wherein the mobile phase includes phase A and phase B; and collecting the peptide solution at a target peak value, and conducting reduced pressure distillation and concentration; and 3) using anion exchange method for converting the trifluoroacetate into acetate, thus obtaining the acetic acid Eptifibatide bulk drug which meets the requirement. In the invention, the method which is applicable to the industrialized purification of Eptifibatide is provided; reversed phase high-performance liquid chromatography is used and combined with the anion exchange method for converting the trifluoroacetate into acetate so as to purify the Eptifibatide; and the purity is high, and the purification yield of the yield reaches more than 70 percent and meets the industrialization requirement.
183. 101531705 Method for purifying Carbetocin
CN
16.09.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200910106758.2
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Cheng Shengqiang
C07K 7/06
Loading...
The invention provides a technological method suitable for the industrialized purification of Carbetocin, a reversed-phase efficient liquid chromatography is used to purify the Carbetocin to result in high purity and good yield in order to meet industrialized demands. A crude peptide solution of the Carbetocin is filled with materials by a reversed-phase chromatographic column to be a stationary phase, a phosphate buffer solution is regarded as phase A and acetonitrile is regarded as phase B to implement gradient elution purification, wherein, the gradient: B%:20-40%, the pH of the phase A is 2.5-3.5; an anion exchange method is employed to convert the phosphate and trifluoroacetate to acetate. The invention employs one-step reversed-phase efficient liquid chromatography to purify followed by the acetate conversion by an anion exchange column in one step, thus obtaining high-purity acetate Carbetocin at high yield and offering an efficient purification technology for the massive purification and preparation of the peptide raw drugs.
184. 101525382 Method of purifying pramlintide
CN
09.09.2009
C07K 14/575 Loading...
C07K 14/575
Loading...
200910106757.8
ShenZhen Hybio Engineering Co., Ltd.
Kang Xu
C07K 14/575
Loading...
The invention discloses a method of purifying pramlintide, belonging to the technical field of HPLC and comprising the steps: 1) after a synthesized coarse peptide is dissolved, a fixed phase serving as reverse silica gel column and mobile phases trifluoroacetic acid aqueous solution as phase A and chromatogram pure acetonitrile as phase B, are used to carry out gradient elution and purification to collect peptide solution of target peak; 2) after the target peptide solution purified in the step 1) is concentrated, and the fixed phase as reverse silica gel column and mobile phases phosphate aqueous solution as phase A and chromatogram pure acetonitrile as phase B, are used to carry out gradient elution and purification to collect peptide solution of target peak; and 3) the phosphate is converted into acetate by anion exchange salt conversion method. The invention purifies pramlintide by the reverse phase high-efficiency liquid phase chromatography and anion exchange method, with high purity and good yield, and provides a process suitable for purifying pramlintide in bulk to reach the industrial requirement.
185. 101519444 Method for preparing Nesiritide
CN
02.09.2009
C07K 14/47 Loading...
C07K 14/47
Loading...
200910104860.9
ShenZhen Hybio Engineering Co., Ltd.
Ouyang Ling
C07K 14/47
Loading...
The invention relates to a method for preparing Nesiritide. In the method, HMPB-AM resin is taken as an initial raw material, amino acids with Fmoc blocking groups are sequentially connected in a solid phase synthesis way under the action of condensing agent and transpeptidase reagent to obtain side chain full-protection linear Nesiritide HMPB-AM resin; linear Nesiritide raw peptides are obtained by schizolysis, Nesiritide raw peptides are obtained by liquid phase oxidation, and Nesiritide fine peptides are obtained by purification, salt transfer and freeze drying. The invention has the advantages of simple operation, easy post treatment, few raw materials, low cost, high yield coefficient, and the like, thereby having considerable economy and utility value and also having extensive application prospect in the polypeptide drug design synthesis field.
186. 101519429 Solid phase method for synchronizing Argatroban
CN
02.09.2009
C07K 5/078 Loading...
C07K 5/078
Loading...
200910106466.9
ShenZhen Hybio Engineering Co., Ltd.
Li Hongling
C07K 5/078
Loading...
The invention discloses a solid phase method for synchronizing Argatroban, including the following steps: (1) (2R, 4R)-N-Fmoc-4-methyl-2-nipecotic acid, macromolecule resin, protective amino acid, coupling reagent and organic base are used as starting raw materials to form (2R, 4R)-N-Fmoc-4-methyl-2-nipecotic acid-resin; (2) Fmoc protection is removed, and a solid phase method is adopted to couple Fmoc-Arg(X)-OH so as to obtain Fmoc-Arg(X)-(2R, 4R)-4-methyl-2-nipecotic acid-resin; (3) the Fmoc protection is removed, and after 3-methyl-1,2,3 4-tetrahydroquinoline-sulfonic acid chloride is coupled, complete full protection Argatroban-resin is obtained; (4) complete peptide protection Argatroban-resin is reacted with a side chain separated blocking group so as to gain the crude product of the Argatroban; and (5) after the operation of recrystallization is carried out, the Argatroban with high purity is obtained. The technical process of the invention has the advantages of simple reaction operation, easy post treatment, less raw material, low cost, more than 80 percent of total yield, considerable economic and practical value as well as broad application prospect in the field of designing and synchronizing polypeptide drugs.
187. 101463080 Method for purifying nesiritide
CN
24.06.2009
C07K 14/47 Loading...
C07K 14/47
Loading...
200910104861.3
Shenzhen Hanyu Pharmaceutical Co., Ltd.
Dai Zhu
C07K 14/47
Loading...
The invention provides a method for purifying Nesritide, mainly comprising the following steps: the crude peptide of the Nesritide is combined with solid phase; the solid phase is eluted by using water and acetonitrile with the ratio of 1-50 : 99-50 as eluate; the eluate is concentrated and gradient elution purification is carried out on the concentrated crude peptide solution by taking octadecylsilane chemically bonded silica as immobile phase, phosphate buffer solution as A phase and chromatographic grade acetonitrile as B phase; phosphate and trifluoroacetate are converted to acetate by an anion exchange method. The purification method is suitable for industrial purification of the Nesritide, has high purity and yield, meets the requirement of industrialization, and provides an effective purification process for purifying and preparing Nesritide raw medicines in quantity.
188. 101372506 Novel process for preparing eptifibatide by purification
CN
25.02.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200710076636.4
Shenzhen Hybio Engineering Co., Ltd.
He Ping
C07K 7/06
Loading...
The invention relates to a new technique for purifying and preparing eptifibatide. At present, the eptifibatide is separated, purified and produced by adopting opposite phase high pressure liquid chromatography. However, mass production is not easy to realize, and the equipment are expensive. Separation and purification are carried out by the method by applying two solvent systems which are not dissolved in each other and make epicyclic motion at high speed in a chromatographic column tube; the processing steps comprises: a. synthetic crude product of the eptifibatide is dissolved by solvent; b. the dissolved crude product of the eptifibatide is separated and purified by high-speed centrifugation separation chromatography (FCPC), and is tested by a uv detector from the distance of 230nm, so that target peak is collected by subsection; c. the collected cut fraction is tested by HPLC, wherein, the cut fraction with the purity higher than 98% is bended to be treated by the next step, and the cut fraction with the purity lower than 98% is recycled and purified again; d. ion exchange is carried out on the cut fraction with qualified purity to remove trifluoroacetic acid (TFA), and then the cut fraction is transformed into acetic acid eptifibatide. The new technique has no irreversible adsorption and the advantages of no loss of sample, no pollution, high speed and high efficiency, and is suitable for mass production.
189. 101372504 Method for purifying desmopressin
CN
25.02.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200710076543.1
Shenzhen Hybio Engineering Co., Ltd.
Qin Liangzheng
C07K 7/06
Loading...
The invention relates to a method for purifying minirin which is mainly used for treating hemophilia, diabetes insipidus, therapeutic haemorrhage control and haemorrhage prevention before surgery, has better effect and little side effect, and is a polypeptide drug with good market prospect. The method adopts the technical proposal that purification in step one: crude peptide which is obtained by synthesis is dissolved and then is treated by gradient elution and purification in a way of taking octadecyl silane linking silica gel as immobile phase, phosphate buffered solution as A phase, and chromatographic grade acetonitrile (ACN) as B phase; purification in step two: the peptide solution obtained by the purification in step one is concentrated and then is treated by gradient elution and purification in a way of taking octadecyl silane linking silica gel as immobile phase, glacial acetic acid solution as A phase, and chromatographic grade acetonitrile (ACN) as B phase. Salt transformation: phosphate and trifluoroacetate are transformed into acetate by adopting the method of anion exchange. The method has the advantages of simple and convenient operation, high product purity, good yield and low cost, achieves industrialization standard, and is beneficial to generalization.
190. 101372505 Method for preparing desmopressin acetate
CN
25.02.2009
C07K 7/06 Loading...
C07K 7/06
Loading...
200710076544.6
Shenzhen Hybio Engineering Co., Ltd.
Liu Jian
C07K 7/06
Loading...
The invention relates to a method for preparing desmopressin acetate. The existing liquidoid synthesis technique is complex in operation, so as to affect popularization. The invention adopts a solid phase synthesis method which comprises steps: 1) Fmoc-Gly-OH and Sieber Amide resin with proper substitutability are started to obtain Fmoc-Gly-Sieber Amide resin with the substitutability in a certain range; 2) the Fmoc-Gly-Sieber Amide resin is synthetized by adopting a coupling way one by one, so as to obtain linearity minirin-Sieber Amide resin; 3) the minirin-Sieber Amide resin is synthetized by adopting solid phase oxidation; 4) finally, the minirin-Sieber Amide resin is disintegrated to obtain crude peptide which is purified and frozen out by high pressure liquidoid, so that the desmopressin acetate is obtained. The method has the characteristics of simple operation in reaction, easy post treatment, high yield, low cost, and the like, and has considerable economical and practical value as well as wide application prospect in the field of the design and synthesis of disulfide linkage ring formation polypeptide drugs.

